The	O
humanistic	O
,	O
economic	O
and	O
societal	O
burden	O
of	O
Herpes	B-DS
Zoster	I-DS
in	O
Europe	O
:	O
a	O
critical	O
review	O

Background	O

Herpes	B-DS
zoster	I-DS
(	O
HZ	B-DS
)	O
or	O
“	O
shingles	B-DS
”	O
is	O
common	O
in	O
persons	O
aged	O
50	O
years	O
or	O
over	O
.	O

HZ	B-DS
is	O
characterised	O
by	O
a	O
painful	O
dermatological	O
rash	O
which	O
typically	O
resolves	O
in	O
approximately	O
one	O
month	O
.	O

Persistent	O
pain	O
for	O
months	O
or	O
years	O
after	O
rash	O
onset	O
,	O
however	O
,	O
is	O
a	O
common	O
complication	O
of	O
HZ	B-DS
;	O
referred	O
to	O
as	O
post	B-DS
-	I-DS
herpetic	I-DS
neuralgia	I-DS
(	O
PHN	B-DS
).	O

Both	O
HZ	B-DS
and	O
PHN	B-DS
have	O
a	O
significant	O
impact	O
on	O
patients	O
’	O
lives	O
,	O
with	O
considerable	O
implications	O
for	O
healthcare	O
systems	O
and	O
wider	O
society	O
.	O

The	O
aim	O
of	O
the	O
present	O
review	O
is	O
to	O
provide	O
comprehensive	O
documentation	O
and	O
critical	O
appraisal	O
of	O
published	O
data	O
concerning	O
the	O
humanistic	O
,	O
economic	O
and	O
societal	O
burden	O
of	O
HZ	B-DS
in	O
Europe	O
.	O

Methods	O

Systematic	O
literature	O
searches	O
were	O
conducted	O
in	O
Medline	O
,	O
EMBASE	O
,	O
PsycINFO	O
,	O
EconLit	O
,	O
HEED	O
and	O
CRD	O
databases	O
.	O

Searches	O
were	O
conducted	O
in	O
July	O
2014	O
and	O
restricted	O
to	O
articles	O
published	O
in	O
the	O
past	O
20	O
years	O
.	O

Articles	O
were	O
selected	O
for	O
full	O
review	O
by	O
two	O
independent	O
researchers	O
in	O
accordance	O
with	O
predefined	O
eligibility	O
criteria	O
.	O

Results	O

From	O
a	O
review	O
of	O
1619	O
abstracts	O
,	O
53	O
eligible	O
articles	O
,	O
were	O
identified	O
which	O
reported	O
data	O
concerning	O
healthcare	O
resource	O
use	O
(	O
n	O
=	O
38	O
),	O
direct	O
costs	O
(	O
n	O
=	O
20	O
),	O
indirect	O
costs	O
(	O
n	O
=	O
16	O
),	O
total	O
costs	O
(	O
n	O
=	O
10	O
)	O
and	O
impact	O
on	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQoL	O
)	O
(	O
n	O
=	O
21	O
).	O

Findings	O
highlight	O
that	O
PHN	B-DS
is	O
associated	O
with	O
greater	O
impairments	O
in	O
HRQoL	O
and	O
higher	O
costs	O
of	O
management	O
than	O
HZ	B-DS
.	O

For	O
both	O
HZ	B-DS
and	O
PHN	B-DS
,	O
pain	O
severity	O
is	O
a	O
significant	O
predictor	O
of	O
impact	O
on	O
individuals	O
,	O
healthcare	O
systems	O
and	O
society	O
.	O

While	O
the	O
incidence	O
of	O
HZ	B-DS
and	O
PHN	B-DS
increase	O
with	O
age	O
,	O
age	O
does	O
not	O
appear	O
to	O
be	O
a	O
key	O
driver	O
of	O
overall	O
costs	O
for	O
HZ	B-DS
and	O
PHN	B-DS
.	O

Specifically	O
,	O
while	O
direct	O
costs	O
(	O
e	O
.	O
g	O
.	O
GP	O
,	O
specialists	O
,	O
medications	O
,	O
hospitalisations	O
)	O
tend	O
to	O
be	O
higher	O
for	O
older	O
patients	O
,	O
indirect	O
costs	O
(	O
e	O
.	O
g	O
.	O
work	O
time	O
missed	O
)	O
are	O
higher	O
for	O
younger	O
patients	O
.	O

Conclusions	O

Available	O
evidence	O
highlights	O
that	O
HZ	B-DS
and	O
PHN	B-DS
result	O
in	O
significant	O
humanistic	O
and	O
economic	O
burden	O
for	O
patients	O
,	O
healthcare	O
systems	O
and	O
wider	O
societies	O
.	O

A	O
tendency	O
to	O
focus	O
upon	O
healthcare	O
resource	O
use	O
and	O
the	O
direct	O
costs	O
of	O
management	O
at	O
the	O
expense	O
of	O
other	O
impacts	O
(	O
e	O
.	O
g	O
.	O
informal	O
caregivers	O
and	O
formal	O
social	O
care	O
)	O
may	O
result	O
in	O
an	O
underestimation	O
of	O
the	O
true	O
burden	O
of	O
HZ	B-DS
and	O
PHN	B-DS
.	O

Background	O

Herpes	B-DS
zoster	I-DS
(	O
HZ	B-DS
),	O
also	O
known	O
as	O
shingles	B-DS
,	O
is	O
caused	O
by	O
the	O
reactivation	O
of	O
the	O
varicella	B-OG
zoster	I-OG
virus	I-OG
(	O
VZV	B-OG
).	O

Primary	O
infection	B-DS
with	O
VZV	B-OG
usually	O
occurs	O
during	O
childhood	O
,	O
manifesting	O
as	O
chickenpox	B-DS
,	O
after	O
which	O
the	O
virus	O
lies	O
dormant	O
[	O
1	O
].	O

The	O
great	O
majority	O
(	O
95	O
%)	O
[	O
2	O
]	O
of	O
the	O
population	O
hosts	O
VZV	B-OG
and	O
approximately	O
one	O
in	O
four	O
persons	O
will	O
develop	O
HZ	B-DS
in	O
their	O
lifetime	O
through	O
reactivation	O
,	O
leading	O
to	O
an	O
estimated	O
1	O
.	O
7	O
million	O
episodes	O
in	O
Europe	O
annually	O
[	O
3	O
].	O

VZV	B-OG
reactivation	O
is	O
primarily	O
related	O
to	O
an	O
age	O
-	O
related	O
decline	O
in	O
VZV	B-OG
-	O
specific	O
immunity	O
;	O
it	O
is	O
well	O
documented	O
that	O
the	O
incidence	O
of	O
HZ	B-DS
increases	O
with	O
age	O
,	O
with	O
the	O
majority	O
of	O
cases	O
occurring	O
in	O
patients	O
over	O
50	O
years	O
of	O
age	O
[	O
4	O
].	O

HZ	B-DS
is	O
characterized	O
by	O
a	O
painful	O
dermatomal	O
rash	O
,	O
which	O
most	O
commonly	O
presents	O
on	O
the	O
trunk	O
and	O
lumbar	O
regions	O
.	O

HZ	B-DS
,	O
however	O
,	O
may	O
present	O
along	O
any	O
nerve	O
including	O
the	O
ophthalmic	O
division	O
of	O
the	O
trigeminal	O
nerve	O
where	O
it	O
can	O
affect	O
the	O
eye	O
.	O

Herpes	B-DS
Zoster	I-DS
Ophthalmicus	I-DS
(	O
HZO	B-DS
)	O
occurs	O
in	O
10	O
-	O
20	O
%	O
of	O
all	O
HZ	B-DS
cases	O
and	O
in	O
some	O
cases	O
can	O
lead	O
to	O
ocular	O
complications	O
[	O
5	O
].	O

The	O
dermatological	O
rash	O
and	O
pain	O
associated	O
with	O
HZ	B-DS
typically	O
resolves	O
within	O
one	O
month	O
of	O
presentation	O
[	O
4	O
];	O
however	O
,	O
long	O
-	O
term	O
complications	O
can	O
arise	O
.	O

Post	B-DS
-	I-DS
herpetic	I-DS
neuralgia	I-DS
(	O
PHN	B-DS
)	O
is	O
the	O
most	O
common	O
and	O
debilitating	O
complication	O
of	O
HZ	B-DS
,	O
occurring	O
in	O
approximately	O
10	O
-	O
20	O
%	O
of	O
all	O
sufferers	O
[	O
6	O
-	O
8	O
]	O
and	O
as	O
many	O
as	O
50	O
%	O
of	O
those	O
aged	O
85	O
years	O
and	O
over	O
[	O
9	O
].	O

PHN	B-DS
is	O
a	O
neuropathic	B-DS
syndrome	I-DS
manifesting	O
as	O
on	O
-	O
going	O
pain	O
along	O
the	O
nerves	O
in	O
the	O
area	O
of	O
the	O
prior	O
HZ	B-DS
rash	O
and	O
typically	O
involves	O
one	O
or	O
more	O
of	O
the	O
following	O
:	O
spontaneous	O
aching	O
or	O
burning	O
;	O
paroxysmal	O
shooting	O
pains	O
;	O
allodynia	O
,	O
and	O
hyperalgesia	O
[	O
9	O
,	O
10	O
].	O

There	O
is	O
no	O
consensus	O
regarding	O
the	O
definition	O
of	O
PHN	B-DS
;	O
however	O
,	O
PHN	B-DS
is	O
often	O
defined	O
as	O
pain	O
persisting	O
for	O
90	O
days	O
from	O
HZ	B-DS
rash	O
onset	O
[	O
4	O
,	O
6	O
,	O
10	O
,	O
11	O
].	O

While	O
HZ	B-DS
is	O
an	O
acute	O
experience	O
that	O
typically	O
resolves	O
within	O
one	O
month	O
,	O
in	O
the	O
majority	O
of	O
sufferers	O
,	O
PHN	B-DS
persists	O
for	O
at	O
least	O
6	O
months	O
with	O
some	O
patients	O
experiencing	O
PHN	B-DS
for	O
years	O
[	O
12	O
-	O
15	O
].	O

As	O
expected	O
given	O
the	O
relationship	O
to	O
HZ	B-DS
,	O
the	O
incidence	O
of	O
PHN	B-DS
increases	O
markedly	O
with	O
age	O
[	O
16	O
-	O
18	O
].	O

The	O
incidence	O
of	O
PHN	B-DS
is	O
also	O
linked	O
to	O
the	O
severity	O
of	O
pain	O
experienced	O
during	O
the	O
prior	O
HZ	B-DS
episode	O
(	O
among	O
other	O
predictors	O
such	O
as	O
the	O
severity	O
of	O
the	O
dermatomal	O
rash	O
and	O
prodromal	O
symptoms	O
)	O
[	O
19	O
],	O
with	O
those	O
patients	O
experiencing	O
the	O
highest	O
levels	O
of	O
pain	O
during	O
HZ	B-DS
presentation	O
being	O
most	O
at	O
risk	O
of	O
developing	O
PHN	B-DS
[	O
20	O
].	O

As	O
conditions	O
primarily	O
affecting	O
older	O
persons	O
,	O
many	O
patients	O
with	O
HZ	B-DS
and	O
PHN	B-DS
may	O
already	O
experience	O
significant	O
deficits	O
in	O
health	O
status	O
.	O

Findings	O
from	O
a	O
number	O
of	O
articles	O
indicate	O
that	O
the	O
pain	O
and	O
resulting	O
discomfort	O
associated	O
with	O
HZ	B-DS
and	O
PHN	B-DS
can	O
have	O
a	O
substantial	O
negative	O
and	O
widespread	O
impact	O
on	O
patients	O
’	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQoL	O
)	O
and	O
patients	O
’	O
ability	O
to	O
engage	O
in	O
activities	O
of	O
daily	O
living	O
[	O
7	O
,	O
20	O
-	O
25	O
].	O

In	O
addition	O
to	O
the	O
burden	O
encountered	O
by	O
the	O
individual	O
with	O
HZ	B-DS
,	O
the	O
condition	O
is	O
also	O
associated	O
with	O
considerable	O
economic	O
burden	O
.	O

For	O
example	O
,	O
considerable	O
costs	O
to	O
healthcare	O
systems	O
[	O
26	O
-	O
31	O
]	O
arise	O
from	O
the	O
care	O
provision	O
for	O
HZ	B-DS
and	O
PHN	B-DS
patients	O
,	O
including	O
visits	O
to	O
primary	O
care	O
(	O
general	O
practitioner	O
)	O
and	O
outpatient	O
secondary	O
/	O
tertiary	O
care	O
(	O
specialist	O
pain	O
clinics	O
and	O
ophthalmologists	O
),	O
inpatient	O
visits	O
(	O
hospitalisations	O
)	O
and	O
prescription	O
costs	O
.	O

Furthermore	O
,	O
HZ	B-DS
and	O
PHN	B-DS
are	O
also	O
associated	O
with	O
significant	O
indirect	O
costs	O
,	O
primarily	O
in	O
terms	O
of	O
loss	O
of	O
productivity	O
for	O
younger	O
patients	O
[	O
7	O
,	O
21	O
,	O
23	O
,	O
24	O
,	O
28	O
,	O
32	O
].	O

Finally	O
,	O
as	O
conditions	O
occurring	O
in	O
retired	O
and	O
older	O
patients	O
,	O
HZ	B-DS
and	O
PHN	B-DS
can	O
also	O
have	O
significant	O
consequences	O
for	O
the	O
caregivers	O
of	O
patients	O
including	O
partners	O
,	O
relatives	O
,	O
and	O
friends	O
of	O
people	O
with	O
the	O
conditions	O
[	O
7	O
].	O

Such	O
details	O
,	O
however	O
,	O
may	O
often	O
go	O
unreported	O
and	O
are	O
not	O
often	O
communicated	O
in	O
the	O
research	O
literature	O
.	O

Evidence	O
for	O
the	O
efficacy	O
of	O
a	O
VZV	B-OG
vaccine	O
in	O
the	O
prevention	O
of	O
HZ	B-DS
and	O
PHN	B-DS
episodes	O
and	O
attenuation	O
of	O
the	O
severity	O
of	O
HZ	B-DS
and	O
PHN	B-DS
episodes	O
and	O
associated	O
impact	O
has	O
been	O
documented	O
in	O
recent	O
years	O
[	O
11	O
,	O
33	O
].	O

In	O
order	O
to	O
understand	O
the	O
value	O
of	O
preventative	O
strategies	O
,	O
a	O
complete	O
understanding	O
of	O
the	O
impact	O
of	O
HZ	B-DS
and	O
PHN	B-DS
is	O
required	O
.	O

While	O
a	O
significant	O
body	O
of	O
literature	O
has	O
sought	O
to	O
determine	O
the	O
impact	O
of	O
HZ	B-DS
and	O
PHN	B-DS
on	O
patients	O
,	O
healthcare	O
systems	O
and	O
wider	O
society	O
within	O
EU	O
countries	O
,	O
to	O
date	O
,	O
no	O
comprehensive	O
review	O
of	O
these	O
studies	O
has	O
been	O
conducted	O
.	O

The	O
aim	O
of	O
this	O
review	O
,	O
therefore	O
,	O
is	O
to	O
provide	O
a	O
comprehensive	O
and	O
holistic	O
overview	O
of	O
the	O
humanistic	O
,	O
economic	O
and	O
societal	O
burden	O
of	O
HZ	B-DS
and	O
PHN	B-DS
in	O
Europe	O
as	O
reported	O
within	O
the	O
published	O
peer	O
-	O
reviewed	O
literature	O
.	O

Methods	O

Published	O
peer	O
-	O
reviewed	O
articles	O
were	O
identified	O
via	O
systematic	O
searches	O
conducted	O
in	O
the	O
following	O
biomedical	O
and	O
economic	O
databases	O
:	O
EMBASE	O
,	O
Medline	O
,	O
PsycINFO	O
,	O
EconLit	O
,	O
Health	O
Economic	O
Evaluations	O
Database	O
(	O
HEED	O
)	O
and	O
the	O
Centre	O
for	O
Reviews	O
and	O
Dissemination	O
databases	O
at	O
the	O
University	O
of	O
York	O
.	O

Searches	O
and	O
reviews	O
were	O
conducted	O
in	O
accordance	O
with	O
the	O
Cochrane	O
systematic	O
review	O
guidelines	O
[	O
34	O
].	O

A	O
range	O
of	O
disease	O
-	O
related	O
,	O
economic	O
,	O
societal	O
and	O
HRQoL	O
-	O
related	O
keywords	O
was	O
utilized	O
to	O
capture	O
the	O
humanistic	O
,	O
economic	O
and	O
societal	O
burden	O
of	O
HZ	B-DS
and	O
PHN	B-DS
(	O
see	O
Table	O
1	O
).	O

Searches	O
were	O
conducted	O
in	O
July	O
2014	O
and	O
were	O
restricted	O
to	O
articles	O
published	O
in	O
the	O
last	O
20	O
years	O
.	O

Although	O
data	O
relating	O
to	O
the	O
EU	O
was	O
the	O
primary	O
focus	O
of	O
this	O
review	O
,	O
no	O
limits	O
regarding	O
study	O
country	O
or	O
article	O
language	O
were	O
implemented	O
during	O
the	O
search	O
stage	O
(	O
so	O
to	O
not	O
exclude	O
potentially	O
relevant	O
articles	O
).	O

Instead	O
,	O
articles	O
focused	O
on	O
the	O
EU	O
were	O
prioritized	O
as	O
part	O
of	O
the	O
article	O
selection	O
process	O
.	O
Table	O
1Search	O
terms	O
Databases	O
searched	O
Disease	O
search	O
terms	O
Economic	O
,	O
humanistic	O
and	O
societal	O
burden	O
search	O
terms	O
•	O
Medline	O
“	O
Herpes	B-DS
Zoster	I-DS
”	O
OR	O
“	O
Shingles	B-DS
”	O
OR	O
“	O
Post	B-DS
-	I-DS
herpetic	I-DS
Neuralgia	I-DS
”	O
OR	O
“	O
Post	B-DS
herpetic	I-DS
Neuralgia	I-DS
”	O
OR	O
“	O
Postherpetic	B-DS
Neuralgia	I-DS
”	O
OR	O
“	O
PHN	B-DS
”“	O
Burden	O
”	O
OR	O
“	O
Humanistic	O
”	O
OR	O
“	O
quality	O
of	O
life	O
”	O
OR	O
“	O
QOL	O
”	O
OR	O
“	O
HRQOL	O
”	O
OR	O
“	O
cost	O
”	O
OR	O
“	O
economic	O
”	O
OR	O
“	O
resource	O
”	O
OR	O
“	O
society	O
”	O
OR	O
“	O
societal	O
”	O
OR	O
“	O
family	O
”	O
OR	O
“	O
relatives	O
”	O
OR	O
“	O
Caregiver	O
”	O
OR	O
“	O
care	O
$”	O
OR	O
“	O
activities	O
of	O
daily	O
living	O
”	O
OR	O
“	O
ADLS	O
”	O
OR	O
“	O
daily	O
activities	O
”	O
OR	O
“	O
cost	O
of	O
illness	O
”	O
OR	O
“	O
autonomy	O
”	O
OR	O
“	O
hospitalisation	O
”	O
OR	O
“	O
hospitalization	O
”	O
•	O
Embase	O
•	O
PscyINFO	O
•	O
EconLit	O
.	O
•	O
Health	O
Economic	O
Evaluations	O
Database	O
(	O
HEED	O
)	O
•	O
Centre	O
for	O
Reviews	O
and	O
Dissemination	O
databases	O
:	O
-	O
Database	O
of	O
Abstracts	O
of	O
Reviews	O
of	O
Effects	O
(	O
DARE	O
),	O
-	O
Health	O
Technology	O
Assessment	O
(	O
HTA	O
)	O
-	O
NHS	O
Economic	O
Evaluation	O
Database	O
(	O
NHS	O
EED	O
)	O

In	O
accordance	O
with	O
Cochrane	O
review	O
guidelines	O
[	O
35	O
],	O
all	O
abstracts	O
were	O
reviewed	O
by	O
two	O
researchers	O
independently	O
according	O
to	O
formal	O
inclusion	O
/	O
exclusion	O
criteria	O
(	O
Table	O
2	O
).	O

For	O
inclusion	O
in	O
the	O
review	O
,	O
abstracts	O
were	O
required	O
present	O
information	O
specific	O
to	O
adult	O
patients	O
in	O
the	O
EU	O
and	O
to	O
contain	O
information	O
pertaining	O
to	O
the	O
key	O
search	O
terms	O
(	O
see	O
Table	O
1	O
).	O

In	O
instances	O
were	O
aforementioned	O
details	O
were	O
not	O
clear	O
from	O
the	O
abstract	O
,	O
full	O
text	O
articles	O
were	O
obtained	O
to	O
confirm	O
whether	O
the	O
article	O
should	O
be	O
included	O
/	O
excluded	O
.	O

Real	O
world	O
data	O
,	O
observational	O
studies	O
,	O
effectiveness	O
studies	O
,	O
qualitative	O
studies	O
,	O
economic	O
evaluations	O
and	O
cost	O
studies	O
were	O
all	O
considered	O
relevant	O
for	O
review	O
.	O

The	O
final	O
list	O
of	O
abstracts	O
and	O
articles	O
for	O
full	O
in	O
-	O
depth	O
review	O
was	O
agreed	O
following	O
consensus	O
between	O
the	O
authors	O
.	O
Table	O
2	O
Study	O
Inclusion	O
/	O
exclusion	O
criteria	O
Inclusion	O
criteria	O
Exclusion	O
criteria	O
Country	O
setting	O
Present	O
data	O
from	O
a	O
country	O
in	O
the	O
EU	O
or	O
EU	O
in	O
general	O
Only	O
present	O
data	O
from	O
a	O
non	O
-	O
EU	O
country	O
.	O

No	O
data	O
specific	O
to	O
the	O
EU	O
.	O
Population	O
Adults	O
with	O
HZ	B-DS
or	O
PHN	B-DS
Children	O
Focus	O
mainly	O
on	O
chicken	O
pox	O
Immunodepressed	O
patients	O
only	O
(	O
e	O
.	O
g	O
.	O
HIV	B-OG
patients	O
)	O
Studies	O
that	O
contain	O
information	O
on	O
key	O
search	O
terms	O
(	O
inc	O
.	O

QoL	O
,	O
burden	O
,	O
productivity	O
)	O
Studies	O
that	O
do	O
NOT	O
contain	O
information	O
on	O
key	O
search	O
terms	O
Study	O
design	O
Real	O
world	O
data	O
,	O
observational	O
studies	O
,	O
effectiveness	O
,	O
qualitative	O
research	O
and	O
cost	O
studies	O
Clinical	O
trials	O
of	O
efficacy	O
and	O
safety	O
of	O
treatments	O
presenting	O
QoL	O
data	O
as	O
secondary	O
endpoint	O
only	O
Clinical	O
trials	O
of	O
Zostavax	O
Focus	O
mainly	O
on	O
epidemiological	O
evidence	O
(	O
e	O
.	O
g	O
.	O
incidence	O
,	O
prevalence	O
etc	O
.)	O
Publication	O
type	O
For	O
conference	O
abstracts	O
,	O
exclusion	O
if	O
manuscript	O
corresponding	O
to	O
this	O
abstract	O
and	O
presenting	O
equivalent	O
information	O
is	O
already	O
published	O

Data	O
extraction	O
tables	O
were	O
developed	O
to	O
accurately	O
record	O
information	O
from	O
the	O
articles	O
chosen	O
for	O
review	O
.	O

Of	O
importance	O
was	O
information	O
related	O
to	O
the	O
study	O
aims	O
,	O
design	O
and	O
outcomes	O
of	O
interest	O
,	O
sample	O
characteristics	O
,	O
country	O
of	O
study	O
,	O
resource	O
use	O
data	O
,	O
cost	O
data	O
(	O
direct	O
and	O
indirect	O
)	O
and	O
any	O
patient	O
-	O
reported	O
impacts	O
of	O
HZ	B-DS
and	O
PHN	B-DS
.	O

All	O
referenced	O
costs	O
are	O
provided	O
in	O
Euros	O
and	O
have	O
been	O
adjusted	O
to	O
the	O
same	O
price	O
year	O
(	O
2015	O
)	O
based	O
on	O
annual	O
average	O
rate	O
of	O
change	O
(%)	O
in	O
the	O
Harmonised	O
Index	O
of	O
Consumer	O
Prices	O
[	O
36	O
].	O

Results	O

Search	O
results	O

Figure	O
1	O
provides	O
an	O
overview	O
of	O
the	O
article	O
selection	O
process	O
.	O

A	O
total	O
of	O
1619	O
titles	O
and	O
abstracts	O
were	O
reviewed	O
against	O
the	O
inclusion	O
/	O
exclusion	O
criteria	O
,	O
resulting	O
in	O
78	O
EU	O
based	O
articles	O
for	O
full	O
text	O
review	O
.	O

A	O
further	O
25	O
articles	O
were	O
excluded	O
following	O
full	O
text	O
review	O
,	O
leaving	O
a	O
total	O
of	O
53	O
studies	O
to	O
be	O
included	O
in	O
this	O
review	O
.	O
Figure	O
1	O
Overview	O
of	O
study	O
selection	O
for	O
review	O
.	O

Overview	O
of	O
selected	O
articles	O

A	O
summary	O
of	O
the	O
53	O
articles	O
selected	O
for	O
inclusion	O
in	O
the	O
review	O
(	O
including	O
study	O
countries	O
,	O
population	O
,	O
data	O
presented	O
)	O
is	O
provided	O
in	O
Table	O
3	O
.	O
Table	O
3	O
Overview	O
of	O
included	O
studies	O
Author	O
and	O
year	O
Country	O
perspective	O
Population	O
Healthcare	O
utilisation	O
Economic	O
data	O
HRQoL	O
HZ	B-DS
HZ	B-DS
and	O
PHN	B-DS
PHN1	O
PHN3	O
PHN	B-DS
Other	O
/	O
Undefined	O
Direct	O
costs	O
Indirect	O
costs	O
Total	O
costs	O
Annemans	O
et	O
al	O
.	O
(	O
2010	O
)	O
[	O
26	O
]	O
Belgium	O
✓	O
X	O
✓✓	O
X	O
✓✓✓✓	O
XBayas	O
et	O
al	O
.	O
(	O
2011	O
)	O
[	O
37	O
]	O
Spain	O
CataloniaX	O
✓	O
XXX	O
✓✓	O
XXXBerrut	O
,	O
G	O
.	O
and	O
C	O
.	O

Baptiste	O
(	O
2013	O
)	O
[	O
38	O
]	O
France	O
✓	O
XXXX	O
✓	O
XXXXBlein	O
,	O
C	O
.,	O
et	O
al	O
.	O
(	O
2013	O
)	O
[	O
39	O
]	O
France	O
✓	O
XXXX	O
✓	O
XXXXBilcke	O
et	O
al	O
.	O
(	O
2012	O
)	O
[	O
40	O
]	O
BelgiumX	O
✓	O
X	O
✓	O
X	O
✓✓✓	O
XXBouhassira	O
et	O
al	O
.	O
(	O
2012	O
)	O
[	O
15	O
]	O
France	O
✓✓	O
X	O
✓	O
XXXXX	O
✓	O
Bresse	O
,	O
X	O
.,	O
et	O
al	O
.	O
(	O
2013	O
)	O
[	O
41	O
]	O
France	O
✓	O
XX	O
✓	O
X	O
✓	O
XXXXBricout	O
,	O
H	O
.,	O
et	O
al	O
.	O
(	O
2013	O
)	O
[	O
42	O
]	O
Italy	O
✓	O
XXXXXX	O
✓	O
X	O
✓	O
Bricout	O
,	O
H	O
.,	O
et	O
al	O
.	O
(	O
2013	O
)	O
[	O
42	O
]	O
Italy	O
✓	O
XX	O
✓	O
X	O
✓	O
XXX	O
✓	O
Brisson	O
et	O
al	O
.	O
(	O
2003	O
)	O
[	O
43	O
]	O
England	O
&	O
WalesX	O
✓	O
XX	O
✓✓✓✓✓	O
XCastro	O
-	O
Lopes	O
,	O
J	O
.	O

M	O
.,	O
et	O
al	O
.	O
(	O
2013	O
)	O
[	O
44	O
]	O
PortugalXXXX	O
✓✓	O
XXX	O
✓	O
Cebrian	O
-	O
Cuenca	O
et	O
al	O
.	O
(	O
2011	O
)	O
[	O
27	O
]	O
Spain	O
,	O
Valencia	O
✓	O
X	O
✓✓	O
X	O
✓✓✓✓	O
XChidiac	O
et	O
al	O
.	O
(	O
2001	O
)	O
[	O
21	O
]	O
France	O
✓✓	O
XX	O
✓✓	O
XXX	O
✓	O
De	O
Juanes	O
et	O
al	O
.	O
(	O
2011	O
)	O
[	O
45	O
]	O
Spain	O
MadridX	O
✓	O
XX	O
✓✓✓	O
XXXDi	O
Legami	O
et	O
al	O
.	O
(	O
2007	O
)	O
[	O
46	O
]	O
Italy	O
–	O
Piemonte	O
✓	O
XXX	O
✓✓✓	O
XXXEdmunds	O
et	O
al	O
.	O
(	O
2001	O
)	O
[	O
47	O
]	O
England	O
and	O
WalesX	O
✓✓	O
XX	O
✓✓	O
XXXFranco	O
,	O
E	O
.,	O
et	O
al	O
.	O
(	O
2013	O
)	O
[	O
48	O
]	O
Italy	O
✓	O
XX	O
✓	O
X	O
✓	O
XXX	O
✓	O
Garcia	O
-	O
Doval	O
et	O
al	O
.	O
(	O
2010	O
)	O
[	O
49	O
]	O
Spain	O
✓	O
XXX	O
✓✓	O
XXXXGater	O
,	O
A	O
.,	O
et	O
al	O
.	O
(	O
2014	O
)	O
[	O
50	O
]	O
UK	O
✓	O
XXXX	O
✓	O
XXX	O
✓	O
Gauthier	O
et	O
al	O
.	O
(	O
2009	O
)	O
[	O
28	O
]	O
UK	O
✓	O
X	O
✓✓	O
X	O
✓✓	O
XX	O
✓	O
Gialloreti	O
et	O
al	O
.	O
(	O
2010	O
)	O
[	O
29	O
]	O
Italy	O
✓	O
X	O
✓✓	O
X	O
✓✓✓✓	O
XGil	O
et	O
al	O
.	O
(	O
2004	O
)	O
[	O
51	O
]	O
Spain	O
✓	O
XXXX	O
✓✓	O
XXXGil	O
et	O
al	O
.	O
(	O
2009	O
)	O
[	O
52	O
]	O
Spain	O
✓	O
XXXX	O
✓✓	O
XXXGil	O
-	O
Prieto	O
et	O
al	O
.	O
(	O
2011	O
)	O
[	O
53	O
]	O
Spain	O
✓	O
XXXX	O
✓✓	O
XXXGil	O
-	O
Prieto	O
,	O
R	O
.,	O
et	O
al	O
.	O
(	O
2014	O
)	O
[	O
54	O
]	O
Spain	O
✓	O
XXXX	O
✓	O
XXXXGonzalez	O
et	O
al	O
.	O
(	O
2010	O
)	O
[	O
55	O
]	O
France	O
✓	O
XXXX	O
✓	O
XXXXLionis	O
et	O
al	O
.	O
(	O
2011	O
)	O
[	O
56	O
]	O
Greece	O
✓	O
X	O
✓	O
XXXXXX	O
✓	O
Loncar	O
,	O
Z	O
.,	O
et	O
al	O
.	O
(	O
2013	O
)	O
[	O
57	O
]	O
Croatia	O
✓	O
XXXX	O
✓	O
XXX	O
✓	O
Lukas	O
et	O
al	O
.	O
(	O
2012	O
)	O
[	O
58	O
]	O
Germany	O
,	O
Spain	O
,	O
Portugal	O
,	O
the	O
Netherlands	O
,	O
Belgium	O
,	O
Sweden	O
and	O
Switzerland	O
✓✓	O
X	O
✓	O
XXX	O
✓	O
X	O
✓	O
Mesquita	O
,	O
M	O
.	O
and	O
F	O
.	O

Froes	O
(	O
2013	O
)	O
[	O
59	O
]	O
Portugal	O
✓	O
XXXX	O
✓	O
XXXXMick	O
et	O
al	O
.	O
(	O
2010	O
)	O
[	O
30	O
]	O
FranceX	O
✓	O
X	O
✓	O
X	O
✓✓✓✓	O
XMoore	O
et	O
al	O
.	O
(	O
2010	O
)	O
[	O
60	O
]	O
UKX	O
✓✓✓	O
XXX	O
✓	O
XXMorant	O
-	O
Talamante	O
,	O
N	O
.,	O
et	O
al	O
.	O
(	O
2013	O
)	O
[	O
61	O
]	O
Spain	O
✓	O
XXXX	O
✓	O
XXXXMordarski	O
et	O
al	O
.	O
(	O
2009	O
)	O
[	O
62	O
]	O
PolandXXXX	O
✓	O
XXXX	O
✓	O
Nilsson	O
,	O
J	O
.,	O
et	O
al	O
.	O
(	O
2013	O
)	O
[	O
63	O
]	O
SwedenX	O
✓	O
XXXXX	O
✓✓	O
XPierik	O
et	O
al	O
.	O
(	O
2012	O
)	O
[	O
64	O
]	O
Holland	O
/	O
the	O
Netherlands	O
✓	O
XXXX	O
✓	O
XXXXRabaud	O
,	O
C	O
.,	O
et	O
al	O
.	O
(	O
2013	O
)	O
[	O
65	O
]	O
France	O
✓	O
X	O
✓✓	O
X	O
✓	O
XXX	O
✓	O
Rehm	O
et	O
al	O
.	O
(	O
2010	O
)	O
[	O
66	O
]	O
14	O
European	O
countries	O
(	O
countries	O
not	O
specified	O
)	O
XX	O
✓	O
XXXXXX	O
✓	O
Schiffner	O
-	O
Rohe	O
et	O
al	O
.	O
(	O
2011	O
)	O
[	O
67	O
]	O
Germany	O
✓	O
X	O
✓	O
XX	O
✓✓	O
X	O
✓	O
XScott	O
et	O
al	O
.	O
(	O
2003	O
)	O
[	O
68	O
]	O
UK	O
✓	O
XX	O
✓	O
XXXXX	O
✓	O
Scott	O
et	O
al	O
.	O
(	O
2006	O
)	O
[	O
7	O
]	O
UKX	O
✓	O
X	O
✓	O
XXX	O
✓✓✓	O
Serpell	O
,	O
M	O
.,	O
et	O
al	O
.	O
(	O
2014	O
)	O
[	O
14	O
]	O
UKXXX	O
✓	O
X	O
✓	O
XXX	O
✓	O
Sicras	O
-	O
Mainar	O
et	O
al	O
.	O
(	O
2012	O
)	O
[	O
69	O
]	O
Spain	O
✓✓	O
XX	O
✓✓✓✓✓	O
XSouliotis	O
,	O
K	O
.,	O
et	O
al	O
.	O
(	O
2013	O
)	O
[	O
70	O
]	O
GreeceX	O
✓	O
XXXX	O
✓✓	O
XXStudahl	O
,	O
M	O
.,	O
et	O
al	O
.	O
(	O
2013	O
)	O
[	O
71	O
]	O
Sweden	O
✓	O
XXXX	O
✓	O
XXXXSzucs	O
(	O
2011	O
)	O
[	O
72	O
]	O
Switzerland	O
✓	O
XX	O
✓✓	O
X	O
✓✓✓	O
XUltsch	O
et	O
al	O
.	O
(	O
2011	O
)	O
[	O
73	O
]	O
Germany	O
✓	O
XX	O
✓	O
X	O
✓	O
XXXXUltsch	O
et	O
al	O
.	O
(	O
2012	O
)	O
[	O
31	O
]	O
Germany	O
✓	O
XX	O
✓	O
X	O
✓✓✓✓	O
XVan	O
Hoek	O
et	O
al	O
.	O
(	O
2009	O
)	O
[	O
74	O
]	O
England	O
and	O
Wales	O
✓	O
XX	O
✓	O
X	O
✓✓	O
XXXVan	O
Seventer	O
et	O
al	O
.	O
(	O
2006	O
)	O
[	O
25	O
]	O
France	O
,	O
Germany	O
,	O
Italy	O
,	O
Netherlands	O
,	O
Spain	O
,	O
UKXXX	O
✓	O
X	O
✓	O
XXX	O
✓	O
Volpi	O
et	O
al	O
.	O
(	O
2007	O
)	O
[	O
75	O
]	O
Italy	O
✓	O
XXXXXXXX	O
✓	O
Volpi	O
et	O
al	O
.	O
(	O
2008	O
)	O
[	O
76	O
]	O
Italy	O
✓✓	O
X	O
✓✓	O
XXXX	O
✓	O
Weinke	O
et	O
al	O
.	O
(	O
2010	O
)	O
[	O
77	O
]	O
Germany	O
✓	O
XX	O
✓	O
XXX	O
✓	O
X	O
✓✓	O
and	O
x	O
indicate	O
the	O
presence	O
/	O
absence	O
of	O
evidence	O
,	O
respectively	O
.	O

The	O
references	O
selected	O
for	O
review	O
presented	O
data	O
from	O
14	O
European	O
countries	O
with	O
the	O
majority	O
(	O
n	O
=	O
39	O
,	O
73	O
.	O
6	O
%)	O
of	O
articles	O
providing	O
data	O
from	O
the	O
‘	O
Big	O
5	O
’	O
EU	O
countries	O
(	O
UK	O
;	O
Spain	O
;	O
France	O
;	O
Germany	O
&	O
Italy	O
).	O

Of	O
the	O
included	O
references	O
,	O
39	O
reported	O
data	O
specifically	O
attributed	O
to	O
HZ	B-DS
patients	O
and	O
35	O
reported	O
data	O
specifically	O
attributed	O
to	O
PHN	B-DS
patients	O
.	O

Data	O
attributed	O
to	O
a	O
combined	O
HZ	B-DS
and	O
PHN	B-DS
population	O
was	O
included	O
in	O
15	O
references	O
.	O

The	O
references	O
eligible	O
for	O
inclusion	O
in	O
the	O
study	O
were	O
all	O
published	O
between	O
2000	O
and	O
2014	O
.	O

Data	O
presented	O
in	O
reviewed	O
references	O
was	O
categorized	O
as	O
follows	O
:	O
1	O
)	O
Healthcare	O
utilisation	O
in	O
terms	O
of	O
rates	O
of	O
medical	O
visits	O
,	O
hospitalisations	O
and	O
medication	O
prescribed	O
,	O
2	O
)	O
Direct	O
costs	O
corresponding	O
to	O
the	O
management	O
of	O
HZ	B-DS
/	O
PHN	B-DS
,	O
3	O
)	O
Indirect	O
costs	O
,	O
4	O
)	O
Total	O
costs	O
and	O
5	O
)	O
Health	O
related	O
quality	O
of	O
life	O
and	O
humanistic	O
burden	O
.	O

Of	O
note	O
,	O
some	O
references	O
contained	O
data	O
pertaining	O
to	O
multiple	O
categories	O
.	O

Healthcare	O
utilisation	O

Information	O
regarding	O
healthcare	O
resource	O
was	O
included	O
in	O
38	O
of	O
the	O
identified	O
references	O
(	O
as	O
summarized	O
in	O
Table	O
3	O
).	O

Data	O
indicated	O
that	O
HZ	B-DS
and	O
PHN	B-DS
are	O
associated	O
with	O
considerable	O
healthcare	O
utilisation	O
,	O
with	O
increased	O
resource	O
use	O
associated	O
with	O
increasing	O
age	O
and	O
the	O
presence	O
of	O
PHN	B-DS
.	O

Data	O
concerning	O
healthcare	O
utilisation	O
was	O
presented	O
in	O
terms	O
of	O
rates	O
of	O
medical	O
visits	O
(	O
including	O
GP	O
and	O
specialist	O
visits	O
),	O
hospitalisations	O
(	O
including	O
duration	O
of	O
stay	O
),	O
use	O
of	O
medications	O
and	O
additional	O
diagnostic	O
/	O
laboratory	O
procedures	O
.	O

Medical	O
visits	O

The	O
majority	O
of	O
patients	O
presenting	O
with	O
HZ	B-DS
will	O
consult	O
their	O
GP	O
at	O
least	O
once	O
[	O
43	O
,	O
50	O
].	O

Reflecting	O
the	O
chronic	O
nature	O
of	O
PHN	B-DS
,	O
higher	O
rates	O
of	O
medical	O
visits	O
(	O
GP	O
and	O
specialist	O
visits	O
)	O
have	O
been	O
reported	O
in	O
PHN	B-DS
patients	O
compared	O
to	O
HZ	B-DS
patients	O
[	O
14	O
,	O
21	O
,	O
27	O
,	O
29	O
,	O
50	O
].	O

For	O
example	O
,	O
reports	O
from	O
a	O
study	O
in	O
Italy	O
indicated	O
that	O
patients	O
over	O
the	O
age	O
of	O
50	O
with	O
HZ	B-DS
made	O
approximately	O
1	O
.	O
9	O
visits	O
to	O
their	O
GP	O
.	O

By	O
contrast	O
,	O
the	O
reported	O
number	O
of	O
visits	O
among	O
patients	O
with	O
PHN	B-DS
was	O
11	O
.	O
9	O
and	O
12	O
.	O
0	O
(	O
PHN	B-DS
-	O
1	O
month	O
and	O
PHN	B-DS
3	O
-	O
months	O
definitions	O
,	O
respectively	O
)	O
[	O
29	O
].	O

The	O
proportion	O
of	O
patients	O
referred	O
to	O
specialists	O
(	O
74	O
%	O
PHN	B-DS
versus	O
18	O
%	O
HZ	B-DS
)	O
and	O
the	O
number	O
of	O
specialist	O
visits	O
per	O
case	O
(	O
3	O
.	O
5	O
and	O
3	O
.	O
9	O
for	O
PHN	B-DS
-	O
1	O
month	O
and	O
PHN	B-DS
3	O
-	O
months	O
vs	O
0	O
.	O
2	O
for	O
HZ	B-DS
)	O
were	O
also	O
higher	O
for	O
PHN	B-DS
patients	O
compared	O
to	O
HZ	B-DS
patients	O
.	O

More	O
frequent	O
specialist	O
visits	O
have	O
also	O
been	O
reported	O
among	O
patients	O
with	O
HZO	B-DS
compared	O
to	O
those	O
with	O
HZ	B-DS
[	O
21	O
].	O

The	O
average	O
annual	O
incidence	O
of	O
herpes	B-DS
zoster	I-DS
GP	O
-	O
consultations	O
has	O
been	O
reported	O
to	O
increase	O
with	O
age	O
from	O
32	O
.	O
8	O
/	O
10	O
,	O
000	O
among	O
those	O
aged	O
<	O
60	O
years	O
,	O
to	O
93	O
.	O
1	O
and	O
113	O
.	O
2	O
/	O
10	O
,	O
000	O
among	O
those	O
aged	O
60	O
–	O
64	O
years	O
and	O
≥	O
65	O
years	O
respectively	O
[	O
64	O
].	O

Similarly	O
,	O
the	O
average	O
number	O
of	O
specialist	O
visits	O
was	O
also	O
higher	O
in	O
patients	O
over	O
the	O
age	O
of	O
50	O
compared	O
to	O
those	O
over	O
the	O
age	O
of	O
14	O
[	O
27	O
].	O

Hospitalisations	O

The	O
rates	O
of	O
hospitalisations	O
due	O
to	O
HZ	B-DS
and	O
/	O
or	O
PHN	B-DS
reported	O
in	O
the	O
literature	O
(	O
generally	O
derived	O
from	O
national	O
or	O
insurance	O
databases	O
of	O
hospital	O
admissions	O
)	O
suggest	O
that	O
increased	O
rates	O
of	O
hospitalisation	O
are	O
also	O
associated	O
with	O
increasing	O
age	O
[	O
55	O
,	O
71	O
].	O

More	O
frequent	O
hospitalisations	O
have	O
also	O
been	O
observed	O
among	O
patients	O
with	O
PHN	B-DS
when	O
compared	O
to	O
patients	O
with	O
HZ	B-DS
across	O
studies	O
in	O
Italy	O
[	O
29	O
],	O
Belgium	O
[	O
40	O
],	O
France	O
[	O
55	O
],	O
Germany	O
[	O
73	O
],	O
Spain	O
[	O
37	O
,	O
45	O
,	O
49	O
,	O
51	O
,	O
52	O
,	O
61	O
].	O
and	O
Portugal	O
[	O
59	O
].	O

There	O
are	O
also	O
reports	O
of	O
a	O
greater	O
rate	O
of	O
hospitalisations	O
among	O
female	O
HZ	B-DS
patients	O
compared	O
to	O
male	O
HZ	B-DS
patients	O
at	O
across	O
all	O
age	O
groups	O
[	O
71	O
].	O

The	O
average	O
length	O
of	O
inpatient	O
stay	O
for	O
PHN	B-DS
(	O
10	O
.	O
2	O
±	O
8	O
.	O
6	O
days	O
)	O
has	O
been	O
reported	O
to	O
be	O
higher	O
than	O
those	O
associated	O
with	O
HZ	B-DS
(	O
7	O
.	O
8	O
±	O
5	O
.	O
4	O
days	O
)	O
[	O
29	O
].	O

The	O
average	O
duration	O
of	O
stay	O
in	O
hospital	O
among	O
HZ	B-DS
patients	O
also	O
appears	O
to	O
be	O
influenced	O
by	O
age	O
[	O
47	O
,	O
74	O
].	O

For	O
example	O
,	O
analysis	O
of	O
Hospital	O
Episode	O
Statistics	O
(	O
2002	O
–	O
2005	O
)	O
from	O
England	O
indicates	O
the	O
average	O
length	O
of	O
stay	O
among	O
HZ	B-DS
/	O
PHN	B-DS
patients	O
aged	O
60	O
–	O
64	O
is	O
9	O
.	O
3	O
days	O
whereas	O
those	O
aged	O
85	O
–	O
90	O
is	O
22	O
.	O
3	O
days	O
[	O
74	O
].	O

Comparisons	O
between	O
HZ	B-DS
and	O
HZO	B-DS
patients	O
over	O
50	O
years	O
of	O
age	O
also	O
indicate	O
longer	O
hospital	O
stays	O
in	O
patients	O
with	O
HZO	B-DS
(	O
9	O
.	O
8	O
vs	O
7	O
.	O
8	O
days	O
)	O
[	O
38	O
].	O

Medication	O
use	O

It	O
is	O
reported	O
that	O
up	O
to	O
100	O
%	O
of	O
PHN	B-DS
patients	O
and	O
83	O
.	O
2	O
%	O
of	O
patients	O
with	O
HZ	B-DS
receive	O
medication	O
for	O
their	O
condition	O
across	O
all	O
ages	O
[	O
31	O
].	O

Polypharmacy	O
is	O
common	O
among	O
HZ	B-DS
patients	O
with	O
HZ	B-DS
patients	O
reported	O
to	O
be	O
taking	O
at	O
least	O
4	O
different	O
medications	O
on	O
average	O
and	O
PHN	B-DS
patients	O
reported	O
to	O
be	O
taking	O
5	O
medications	O
[	O
50	O
].	O

This	O
could	O
potentially	O
have	O
wider	O
implications	O
as	O
polypharmacy	O
is	O
known	O
to	O
be	O
a	O
major	O
cause	O
of	O
drug	O
interactions	O
and	O
issues	O
with	O
treatment	O
adherence	O
and	O
safety	O
[	O
78	O
].	O

The	O
types	O
of	O
medication	O
used	O
has	O
been	O
reported	O
to	O
vary	O
depending	O
on	O
the	O
population	O
being	O
considered	O
(	O
HZ	B-DS
or	O
PHN	B-DS
)	O
[	O
14	O
,	O
21	O
,	O
29	O
,	O
50	O
].	O

Indeed	O
,	O
current	O
treatment	O
of	O
HZ	B-DS
aims	O
to	O
relieve	O
pain	O
,	O
to	O
limit	O
the	O
spread	O
and	O
duration	O
of	O
the	O
dermatomal	O
lesions	O
and	O
(	O
when	O
started	O
within	O
72	O
hours	O
of	O
rash	O
onset	O
)	O
to	O
prevent	O
or	O
alleviate	O
complications	O
associated	O
with	O
HZ	B-DS
.	O

By	O
contrast	O
,	O
for	O
PHN	B-DS
,	O
the	O
focus	O
of	O
medications	O
is	O
to	O
alleviate	O
pain	O
[	O
79	O
,	O
80	O
].	O

The	O
amount	O
of	O
available	O
information	O
regarding	O
medication	O
use	O
in	O
EU	O
countries	O
was	O
somewhat	O
limited	O
;	O
however	O
available	O
evidence	O
from	O
the	O
literature	O
suggests	O
that	O
,	O
despite	O
the	O
availability	O
of	O
European	O
Guidelines	O
for	O
the	O
management	O
of	O
HZ	B-DS
[	O
80	O
,	O
81	O
],	O
medication	O
prescribing	O
practices	O
(	O
for	O
the	O
treatment	O
of	O
PHN	B-DS
in	O
particular	O
)	O
are	O
not	O
consistent	O
across	O
countries	O
[	O
14	O
,	O
21	O
,	O
25	O
,	O
29	O
,	O
44	O
,	O
50	O
].	O

An	O
observational	O
study	O
of	O
PHN	B-DS
patients	O
over	O
the	O
age	O
of	O
50	O
conducted	O
in	O
France	O
,	O
Germany	O
,	O
Italy	O
,	O
Netherlands	O
,	O
Spain	O
and	O
the	O
UK	O
(	O
n	O
=	O
84	O
),	O
for	O
example	O
,	O
reported	O
that	O
neuropathic	O
pain	O
medications	O
(	O
89	O
%),	O
analgesics	O
(	O
64	O
%)	O
and	O
anticonvulsants	O
(	O
52	O
%)	O
were	O
most	O
commonly	O
prescribed	O
for	O
the	O
treatment	O
of	O
PHN	B-DS
[	O
25	O
].	O

However	O
,	O
a	O
study	O
conducted	O
in	O
the	O
UK	O
reported	O
that	O
antidepressants	O
were	O
most	O
commonly	O
prescribed	O
for	O
PHN	B-DS
followed	O
by	O
level	O
1	O
and	O
2	O
analgesics	O
(	O
59	O
.	O
2	O
%,	O
55	O
.	O
3	O
%	O
and	O
50	O
%	O
respectively	O
)	O
[	O
14	O
].	O

Similarly	O
,	O
studies	O
in	O
Italy	O
and	O
Portugal	O
have	O
reported	O
that	O
anticonvulsants	O
to	O
be	O
the	O
most	O
commonly	O
prescribed	O
treatment	O
for	O
PHN	B-DS
,	O
followed	O
by	O
opioid	O
analgesics	O
[	O
29	O
,	O
44	O
].	O

Where	O
reported	O
,	O
medication	O
usage	O
for	O
the	O
treatment	O
of	O
HZ	B-DS
was	O
consistent	O
across	O
studies	O
;	O
with	O
antivirals	O
(	O
typically	O
taken	O
for	O
7	O
days	O
)	O
the	O
most	O
commonly	O
prescribed	O
treatment	O
[	O
14	O
,	O
21	O
,	O
29	O
,	O
42	O
,	O
50	O
,	O
71	O
].	O

Of	O
note	O
,	O
despite	O
the	O
widespread	O
use	O
of	O
pharmacological	O
therapies	O
for	O
the	O
management	O
of	O
HZ	B-DS
and	O
PHN	B-DS
,	O
reports	O
from	O
patients	O
indicate	O
dissatisfaction	O
with	O
treatments	O
,	O
particularly	O
in	O
regards	O
to	O
perceived	O
efficacy	O
[	O
14	O
,	O
50	O
].	O

Diagnostic	O
/	O
laboratory	O
procedures	O

Details	O
of	O
additional	O
investigations	O
among	O
patients	O
with	O
HZ	B-DS
and	O
PHN	B-DS
were	O
reported	O
from	O
studies	O
in	O
France	O
,	O
Italy	O
,	O
Spain	O
and	O
the	O
UK	O
[	O
14	O
,	O
21	O
,	O
27	O
,	O
29	O
,	O
50	O
].	O

Additional	O
investigations	O
reported	O
included	O
blood	O
and	O
urine	O
tests	O
,	O
assessments	O
of	O
inflammation	O
(	O
e	O
.	O
g	O
.	O
erythrocyte	O
sedimentation	O
rate	O
,	O
C	B-GP
-	I-GP
reactive	I-GP
protein	I-GP
level	O
),	O
ophthalmological	O
/	O
ontological	O
examinations	O
,	O
radiology	O
,	O
X	O
-	O
ray	O
,	O
electrocardiograms	O
and	O
ultrasound	O
.	O

Further	O
diagnostic	O
or	O
laboratory	O
examinations	O
were	O
reported	O
in	O
28	O
.	O
0	O
%	O
of	O
incident	O
cases	O
of	O
HZ	B-DS
among	O
an	O
Italian	O
sample	O
of	O
immunocompetent	O
individuals	O
,	O
with	O
the	O
mean	O
number	O
of	O
procedures	O
and	O
examinations	O
reported	O
to	O
be	O
2	O
.	O
6	O
per	O
case	O
[	O
29	O
].	O

By	O
comparison	O
,	O
rates	O
of	O
additional	O
investigations	O
reported	O
in	O
France	O
,	O
Spain	O
and	O
the	O
UK	O
were	O
lower	O
[	O
14	O
,	O
21	O
,	O
27	O
,	O
50	O
],	O
with	O
evidence	O
suggesting	O
that	O
rates	O
of	O
additional	O
investigations	O
were	O
higher	O
in	O
those	O
with	O
PHN	B-DS
(	O
10	O
–	O
12	O
.	O
5	O
%	O
compared	O
to	O
HZ	B-DS
(	O
4	O
.	O
4	O
-	O
9	O
%)	O
[	O
14	O
,	O
21	O
,	O
50	O
].	O

Additional	O
investigations	O
are	O
also	O
more	O
likely	O
among	O
those	O
patients	O
with	O
HZO	B-DS
compared	O
to	O
HZ	B-DS
[	O
21	O
].	O

Direct	O
costs	O
of	O
management	O

Direct	O
costs	O
of	O
the	O
management	O
of	O
HZ	B-DS
and	O
PHN	B-DS
patients	O
were	O
reported	O
in	O
20	O
studies	O
.	O

The	O
reviewed	O
articles	O
presented	O
data	O
from	O
Spain	O
[	O
27	O
,	O
37	O
,	O
45	O
,	O
51	O
-	O
53	O
,	O
69	O
],	O
the	O
UK	O
[	O
7	O
,	O
28	O
,	O
43	O
,	O
47	O
,	O
74	O
],	O
France	O
[	O
30	O
],	O
Italy	O
[	O
29	O
,	O
46	O
],	O
Germany	O
[	O
31	O
,	O
67	O
],	O
Belgium	O
[	O
26	O
,	O
40	O
],	O
Greece	O
[	O
70	O
]	O
and	O
Switzerland	O
[	O
72	O
].	O

Outpatient	O
costs	O
(	O
including	O
medical	O
visits	O
,	O
diagnostic	O
tests	O
and	O
medications	O
),	O
hospitalization	O
and	O
inpatient	O
costs	O
were	O
identified	O
in	O
the	O
literature	O
as	O
key	O
contributors	O
to	O
the	O
overall	O
cost	O
burden	O
of	O
HZ	B-DS
and	O
PHN	B-DS
.	O

Outpatient	O
costs	O

Studies	O
in	O
Belgium	O
[	O
26	O
],	O
Germany	O
[	O
31	O
,	O
67	O
],	O
Italy	O
[	O
29	O
]	O
and	O
the	O
UK	O
[	O
28	O
]	O
have	O
consistently	O
reported	O
higher	O
outpatient	O
management	O
costs	O
(	O
including	O
medical	O
visits	O
,	O
diagnostic	O
tests	O
and	O
medications	O
)	O
among	O
patients	O
who	O
go	O
on	O
to	O
develop	O
PHN	B-DS
.	O

For	O
example	O
,	O
mean	O
direct	O
costs	O
of	O
outpatient	O
management	O
have	O
been	O
reported	O
as	O
€	O
107	O
.	O
98	O
per	O
HZ	B-DS
episode	O
and	O
€	O
406	O
.	O
04	O
and	O
€	O
485	O
.	O
51	O
per	O
PHN	B-DS
episode	O
(	O
1	O
-	O
and	O
3	O
-	O
month	O
definition	O
respectively	O
)	O
[	O
28	O
]	O
a	O
.	O

In	O
addition	O
,	O
costs	O
for	O
outpatient	O
management	O
of	O
HZ	B-DS
and	O
PHN	B-DS
have	O
been	O
reported	O
to	O
increase	O
markedly	O
with	O
pain	O
severity	O
[	O
26	O
,	O
28	O
].	O

For	O
example	O
,	O
outpatient	O
costs	O
among	O
HZ	B-DS
patients	O
ranging	O
from	O
€	O
85	O
.	O
89	O
(	O
no	O
pain	O
)	O
to	O
€	O
178	O
.	O
32	O
(	O
severe	O
pain	O
)	O
per	O
case	O
have	O
been	O
reported	O
in	O
the	O
UK	O
.	O

Reported	O
differences	O
are	O
more	O
pronounced	O
among	O
PHN	B-DS
patients	O
with	O
costs	O
per	O
case	O
ranging	O
from	O
€	O
237	O
.	O
90	O
/	O
284	O
.	O
80	O
(	O
PHN1	O
/	O
PHN3	O
)	O
among	O
patients	O
with	O
mild	O
pain	O
to	O
€	O
741	O
.	O
91	O
/	O
878	O
.	O
88	O
(	O
PHN1	O
/	O
PHN3	O
)	O
among	O
patients	O
with	O
severe	O
pain	O
[	O
28	O
]	O
a	O
.	O

Key	O
differences	O
in	O
the	O
attribution	O
of	O
outpatient	O
costs	O
for	O
HZ	B-DS
and	O
PHN	B-DS
have	O
been	O
reported	O
for	O
Italy	O
;	O
for	O
patients	O
that	O
did	O
not	O
develop	O
PHN	B-DS
,	O
the	O
majority	O
of	O
the	O
cost	O
of	O
management	O
has	O
been	O
reported	O
to	O
be	O
due	O
to	O
the	O
cost	O
of	O
medication	O
(	O
83	O
%)	O
whereas	O
for	O
patients	O
that	O
develop	O
PHN	B-DS
a	O
greater	O
proportion	O
of	O
cost	O
was	O
attributed	O
to	O
diagnostic	O
and	O
investigative	O
procedures	O
[	O
29	O
].	O

Other	O
studies	O
,	O
however	O
,	O
indicate	O
costs	O
of	O
diagnostic	O
procedures	O
to	O
be	O
the	O
smallest	O
contributor	O
to	O
outpatient	O
costs	O
among	O
patients	O
with	O
HZ	B-DS
and	O
PHN	B-DS
(	O
PHN	B-DS
-	O
1	O
and	O
PHN	B-DS
-	O
3	O
)	O
[	O
27	O
].	O

While	O
the	O
average	O
cost	O
of	O
outpatient	O
management	O
per	O
case	O
is	O
higher	O
for	O
patients	O
with	O
PHN	B-DS
than	O
for	O
patients	O
with	O
HZ	B-DS
,	O
when	O
considering	O
overall	O
burden	O
of	O
disease	O
at	O
a	O
country	O
level	O
,	O
the	O
overall	O
cost	O
of	O
disease	O
is	O
higher	O
for	O
HZ	B-DS
.	O

This	O
is	O
primarily	O
a	O
result	O
of	O
the	O
higher	O
incidence	O
rates	O
of	O
HZ	B-DS
.	O

These	O
differences	O
were	O
highlighted	O
by	O
one	O
study	O
which	O
investigated	O
the	O
annual	O
cost	O
of	O
HZ	B-DS
and	O
PHN	B-DS
to	O
healthcare	O
providers	O
located	O
in	O
England	O
and	O
Wales	O
[	O
47	O
].	O

Based	O
on	O
an	O
estimated	O
260	O
,	O
995	O
episodes	O
of	O
HZ	B-DS
occurring	O
annually	O
,	O
with	O
14	O
%	O
of	O
cases	O
developing	O
PHN	B-DS
,	O
an	O
estimated	O
€	O
76	O
.	O
39	O
milliona	O
is	O
spent	O
on	O
the	O
management	O
of	O
HZ	B-DS
(	O
including	O
PHN	B-DS
).	O

Of	O
this	O
,	O
€	O
52	O
.	O
32	O
million	O
was	O
attributable	O
to	O
HZ	B-DS
(€	O
22	O
.	O
47	O
m	O
due	O
to	O
hospitalisation	O
,	O
€	O
19	O
.	O
26	O
m	O
due	O
to	O
prescription	O
medications	O
and	O
€	O
9	O
.	O
63	O
m	O
due	O
to	O
GP	O
consultations	O
)	O
and	O
€	O
24	O
.	O
07	O
million	O
to	O
PHN1	O
(	O
cost	O
breakdown	O
not	O
provided	O
).	O

Similar	O
findings	O
are	O
reported	O
in	O
Germany	O
where	O
statutory	O
health	O
insurance	O
bills	O
have	O
been	O
estimated	O
at	O
€	O
115	O
.	O
5	O
m	O
;	O
€	O
93	O
.	O
5	O
m	O
attributed	O
to	O
HZ	B-DS
treatment	O
and	O
€	O
22	O
m	O
attributed	O
to	O
treatment	O
of	O
PHN	B-DS
[	O
31	O
].	O

Hospitalisation	O
and	O
inpatient	O
costs	O

Hospitalisation	O
costs	O
contribute	O
significantly	O
to	O
the	O
overall	O
direct	O
cost	O
of	O
managing	O
HZ	B-DS
and	O
PHN	B-DS
.	O

Rates	O
of	O
hospitalisation	O
and	O
duration	O
of	O
stay	O
were	O
found	O
to	O
be	O
higher	O
for	O
PHN	B-DS
than	O
for	O
HZ	B-DS
,	O
and	O
to	O
increase	O
with	O
increasing	O
age	O
,	O
translating	O
into	O
higher	O
inpatient	O
costs	O
for	O
patients	O
that	O
develop	O
PHN	B-DS
(	O
Table	O
4	O
)	O
[	O
18	O
,	O
24	O
,	O
33	O
,	O
70	O
].	O

Note	O
that	O
data	O
on	O
hospitalisations	O
and	O
inpatient	O
costs	O
was	O
primarily	O
extracted	O
from	O
a	O
range	O
of	O
national	O
and	O
insurance	O
databases	O
in	O
each	O
country	O
.	O

No	O
studies	O
identified	O
provided	O
a	O
breakdown	O
of	O
the	O
cost	O
elements	O
that	O
are	O
included	O
in	O
a	O
‘	O
hospital	O
stay	O
’.	O
Table	O
4	O
Mean	O
cost	O
per	O
hospitalised	O
case	O
of	O
HZ	B-DS
/	O
PHN	B-DS
,	O
by	O
country	O
Country	O
HZ	B-DS
/	O
PHN	B-DS
HZ	B-DS
(	O
without	O
PHN	B-DS
)	O
PHN	B-DS
Belgium	O
[	O
40	O
]-€	O
5	O
,	O
982	O
(€	O
798	O
-	O
31	O
,	O
689	O
)-(	O
all	O
ages	O
)	O
France	O
[	O
41	O
]-€	O
2	O
,	O
774	O
.	O
28	O
(	O
50	O
+	O
years	O
)€	O
3	O
,	O
731	O
.	O
09	O
(	O
50	O
+	O
years	O
)	O
Germany	O
[	O
31	O
]-€	O
4	O
,	O
189	O
.	O
74	O
(	O
50	O
+	O
years	O
)€	O
4	O
,	O
279	O
.	O
68	O
(	O
50	O
+	O
years	O
)€	O
3	O
,	O
282	O
.	O
64	O
(	O
all	O
ages	O
)€	O
4	O
,	O
112	O
.	O
03	O
(	O
all	O
ages	O
)	O
Italy	O
[	O
29	O
]-€	O
3	O
,	O
188	O
.	O
16	O
±	O
€	O
1	O
,	O
614	O
.	O
99	O
(	O
50	O
+	O
years	O
)€	O
3	O
,	O
451	O
.	O
38	O
±	O
€	O
3	O
,	O
248	O
.	O
43	O
(	O
50	O
+	O
years	O
)	O
Spain	O
[	O
37	O
,	O
45	O
,	O
52	O
,	O
53	O
]€	O
3	O
,	O
366	O
.	O
4	O
-	O
4	O
,	O
505	O
.	O
6	O
€	O
5	O
,	O
019	O
.	O
84	O
(	O
aged	O
40	O
–	O
49	O
)€	O
5	O
,	O
108	O
.	O
04	O
(	O
aged	O
50	O
–	O
59	O
)(	O
all	O
ages	O
)€	O
4	O
,	O
495	O
.	O
68	O
–	O
5	O
,	O
139	O
.	O
54	O
(	O
aged	O
50	O
–	O
59	O
)€	O
4	O
,	O
732	O
.	O
56	O
(	O
aged	O
60	O
–	O
69	O
)€	O
4	O
,	O
210	O
.	O
92	O
–	O
4	O
,	O
782	O
.	O
96	O
(	O
aged	O
60	O
–	O
69	O
)€	O
4	O
,	O
478	O
.	O
04	O
(	O
70	O
+)€	O
4	O
,	O
062	O
.	O
24	O
–	O
4	O
,	O
556	O
.	O
16	O
(	O
aged	O
70	O
+)	O

Indirect	O
costs	O

Indirect	O
costs	O
considered	O
in	O
the	O
EU	O
literature	O
were	O
mainly	O
related	O
to	O
costs	O
associated	O
with	O
sick	O
leave	O
(	O
absenteeism	O
).	O

Seventeen	O
articles	O
reported	O
data	O
on	O
sick	O
leave	O
due	O
to	O
HZ	B-DS
and	O
PHN	B-DS
and	O
the	O
costs	O
that	O
this	O
incurs	O
[	O
7	O
,	O
26	O
,	O
27	O
,	O
29	O
-	O
31	O
,	O
40	O
,	O
42	O
,	O
58	O
,	O
60	O
,	O
63	O
,	O
69	O
,	O
70	O
,	O
72	O
,	O
73	O
,	O
77	O
,	O
82	O
].	O

Absenteeism	O
due	O
to	O
HZ	B-DS
and	O
PHN	B-DS
is	O
a	O
significant	O
cost	O
driver	O
,	O
with	O
increased	O
costs	O
found	O
to	O
be	O
associated	O
with	O
the	O
presence	O
of	O
PHN	B-DS
[	O
29	O
,	O
31	O
,	O
72	O
]	O
and	O
increased	O
levels	O
of	O
pain	O
experienced	O
[	O
26	O
,	O
72	O
].	O

Up	O
to	O
65	O
%	O
of	O
employed	O
patients	O
report	O
work	O
absence	O
due	O
to	O
their	O
disease	O
[	O
77	O
].	O

Costs	O
associated	O
with	O
absenteeism	O
varied	O
across	O
EU	O
countries	O
.	O

In	O
France	O
,	O
these	O
costs	O
accounted	O
for	O
up	O
to	O
30	O
%	O
of	O
the	O
costs	O
of	O
management	O
of	O
HZ	B-DS
from	O
the	O
societal	O
perspective	O
and	O
up	O
to	O
10	O
%	O
of	O
the	O
costs	O
of	O
management	O
for	O
PHN	B-DS
in	O
patients	O
aged	O
50	O
years	O
and	O
over	O
[	O
30	O
].	O

In	O
Germany	O
,	O
the	O
mean	O
annual	O
cost	O
of	O
sick	O
leave	O
due	O
to	O
HZ	B-DS
was	O
€	O
1	O
,	O
504	O
per	O
patient	O
(	O
increasing	O
to	O
€	O
1	O
,	O
826	O
for	O
patients	O
over	O
the	O
age	O
of	O
50	O
),	O
with	O
patients	O
missing	O
an	O
average	O
of	O
12	O
.	O
5	O
days	O
from	O
work	O
.	O

The	O
costs	O
associated	O
with	O
PHN	B-DS
were	O
found	O
to	O
be	O
higher	O
at	O
€	O
7	O
,	O
183	O
(€	O
7	O
.	O
590	O
for	O
patients	O
over	O
50	O
)	O
with	O
patients	O
missing	O
an	O
average	O
of	O
2	O
months	O
from	O
work	O
[	O
31	O
].	O

The	O
average	O
costs	O
associated	O
with	O
absenteeism	O
were	O
found	O
to	O
be	O
lower	O
in	O
Italy	O
and	O
Switzerland	O
than	O
those	O
reported	O
for	O
Germany	O
[	O
29	O
,	O
72	O
].	O

Average	O
costs	O
for	O
patients	O
over	O
the	O
age	O
of	O
50	O
in	O
Italy	O
were	O
€	O
684	O
per	O
case	O
of	O
HZ	B-DS
and	O
€	O
978	O
per	O
case	O
of	O
PHN	B-DS
[	O
29	O
].	O

In	O
Switzerland	O
,	O
reported	O
costs	O
of	O
sick	O
leave	O
per	O
case	O
for	O
patients	O
with	O
varying	O
levels	O
of	O
pain	O
were	O
as	O
follows	O
:	O
mild	O
pain	O
(	O
HZ	B-DS
€	O
335	O
;	O
PHN	B-DS
381	O
),	O
moderate	O
pain	O
(	O
HZ	B-DS
€	O
421	O
;	O
PHN	B-DS
€	O
1	O
,	O
018	O
),	O
severe	O
pain	O
(	O
HZ	B-DS
€	O
1	O
,	O
837	O
;	O
PHN	B-DS
€	O
2	O
,	O
443	O
)	O
b	O
[	O
72	O
].	O

In	O
Spain	O
,	O
the	O
findings	O
from	O
an	O
observational	O
study	O
[	O
27	O
]	O
of	O
130	O
HZ	B-DS
patients	O
aged	O
19	O
–	O
45	O
(	O
median	O
age	O
of	O
63	O
.	O
5	O
yrs	O
)	O
who	O
were	O
observed	O
for	O
1	O
year	O
suggest	O
that	O
an	O
average	O
of	O
4	O
.	O
3	O
hours	O
of	O
work	O
were	O
missed	O
per	O
patient	O
at	O
a	O
cost	O
of	O
€	O
52	O
.	O
98	O
.	O

This	O
study	O
also	O
found	O
that	O
a	O
total	O
of	O
6	O
work	O
hours	O
were	O
lost	O
by	O
carers	O
across	O
the	O
study	O
sample	O
of	O
130	O
,	O
resulting	O
in	O
a	O
total	O
loss	O
of	O
€	O
86	O
.	O
31	O
.	O

The	O
cost	O
and	O
time	O
implications	O
of	O
time	O
taken	O
off	O
work	O
by	O
carers	O
were	O
also	O
considered	O
in	O
two	O
further	O
studies	O
that	O
were	O
conducted	O
in	O
Belgium	O
and	O
the	O
UK	O
respectively	O
.	O

The	O
study	O
conducted	O
in	O
Belgium	O
found	O
that	O
14	O
/	O
184	O
patients	O
reported	O
that	O
someone	O
else	O
could	O
not	O
go	O
to	O
work	O
due	O
to	O
their	O
illness	O
for	O
between	O
0	O
.	O
5	O
-	O
10days	O
,	O
resulting	O
in	O
an	O
average	O
loss	O
of	O
€	O
52	O
per	O
case	O
due	O
to	O
carer	O
absenteeism	O
[	O
40	O
].	O

For	O
the	O
study	O
conducted	O
in	O
the	O
UK	O
,	O
among	O
70	O
HZ	B-DS
patients	O
,	O
a	O
total	O
of	O
52	O
work	O
days	O
were	O
lost	O
by	O
their	O
carers	O
[	O
7	O
].	O

However	O
as	O
the	O
majority	O
of	O
the	O
reviewed	O
studies	O
usually	O
do	O
not	O
report	O
the	O
cost	O
burden	O
associated	O
with	O
time	O
lost	O
by	O
carers	O
this	O
cost	O
is	O
likely	O
to	O
be	O
underestimated	O
.	O

Total	O
costs	O
of	O
management	O

A	O
total	O
of	O
10	O
studies	O
reported	O
the	O
total	O
cost	O
per	O
case	O
of	O
HZ	B-DS
and	O
/	O
or	O
PHN	B-DS
in	O
EU	O
countries	O
,	O
taking	O
into	O
account	O
both	O
direct	O
costs	O
(	O
including	O
medical	O
visits	O
,	O
medications	O
and	O
hospitalisations	O
)	O
and	O
indirect	O
costs	O
(	O
including	O
time	O
missed	O
from	O
work	O
).	O

Table	O
5	O
presents	O
the	O
average	O
cost	O
per	O
case	O
in	O
each	O
country	O
based	O
on	O
the	O
data	O
that	O
was	O
detailed	O
in	O
the	O
reviewed	O
literature	O
.	O

Overall	O
,	O
higher	O
costs	O
were	O
consistently	O
associated	O
with	O
the	O
presence	O
of	O
PHN	B-DS
and	O
increased	O
levels	O
of	O
pain	O
.	O

Of	O
note	O
,	O
whilst	O
HZ	B-DS
and	O
PHN	B-DS
are	O
associated	O
with	O
higher	O
costs	O
to	O
healthcare	O
providers	O
in	O
elderly	O
populations	O
,	O
costs	O
to	O
society	O
in	O
terms	O
of	O
time	O
missed	O
for	O
work	O
tends	O
to	O
be	O
lower	O
,	O
so	O
the	O
total	O
costs	O
overall	O
are	O
similar	O
across	O
age	O
groups	O
[	O
60	O
].	O
Table	O
5	O
Mean	O
total	O
cost	O
of	O
management	O
per	O
HZ	B-DS
or	O
PHN	B-DS
case	O
Country	O
Population	O
age	O
Cost	O
per	O
case	O
HZ	B-DS
PHN1	O
*	O
PHN3	O
^	O
Belgium	O
[	O
26	O
]	O
Aged	O
≥	O
50	O
€	O
118	O
(	O
no	O
pain	O
)€	O
156	O
.	O
94	O
(	O
mild	O
pain	O
)€	O
329	O
.	O
22	O
(	O
mild	O
pain	O
)€	O
1	O
,	O
150	O
.	O
50	O
(	O
severe	O
pain	O
)€	O
1	O
,	O
085	O
.	O
60	O
(	O
severe	O
pain	O
)€	O
2	O
,	O
037	O
.	O
86	O
(	O
severe	O
pain	O
)	O
France	O
[	O
30	O
]	O
Aged	O
≥	O
50	O
€	O
419	O
.	O
87	O
(	O
271	O
–	O
586	O
)€	O
672	O
.	O
76	O
(	O
451	O
–	O
968	O
)-	O
Germany	O
[	O
31	O
]	O
Aged	O
≥	O
50	O
€	O
388	O
.	O
30	O
(	O
354	O
–	O
425	O
)-€	O
1	O
,	O
427	O
.	O
80	O
(	O
1	O
,	O
002	O
-	O
1	O
,	O
917	O
)	O
Germany	O
[	O
67	O
]	O
Aged	O
≥	O
50	O
€	O
729	O
.	O
57	O
€	O
2	O
,	O
167	O
.	O
89Italy	O
[	O
29	O
]	O
Aged	O
≥	O
50	O
€	O
888	O
.	O
06	O
-€	O
1	O
,	O
66	O
.	O
65Spain	O
[	O
27	O
]	O
Aged	O
>	O
14	O
Overall	O
:	O
€	O
446	O
.	O
04	O
(	O
SD	O
508	O
.	O
58	O
)€	O
647	O
.	O
82	O
(	O
SD	O
684	O
.	O
4	O
)€	O
968	O
.	O
78	O
(	O
SD	O
803	O
.	O
58	O
)	O
50	O
-	O
59	O
:	O
€	O
282	O
.	O
06	O
(	O
SD	O
273	O
.	O
15	O
)	O
60	O
-	O
69	O
:€	O
510	O
.	O
52	O
(	O
SD	O
512	O
.	O
73	O
)	O
>	O
70	O
:	O
€	O
422	O
.	O
91	O
(	O
SD	O
388	O
.	O
66	O
)	O
Spain	O
[	O
69	O
]	O
Aged	O
>	O
30	O
€	O
460	O
.	O
95	O
€	O
1	O
,	O
956	O
.	O
15	O
-	O
Sweden	O
[	O
63	O
]	O
All	O
ages	O
€	O
902	O
.	O
88	O
(	O
HZ	B-DS
and	O
PHN	B-DS
)	O
Switzerland	O
[	O
72	O
]	O
Aged	O
≥	O
50	O
€	O
394	O
.	O
46	O
(	O
no	O
pain	O
)-€	O
381	O
.	O
15	O
(	O
no	O
pain	O
)€	O
1	O
,	O
835	O
.	O
57	O
(	O
severe	O
pain	O
)€	O
2	O
,	O
442	O
.	O
99	O
(	O
severe	O
pain	O
)	O
UK	O
[	O
7	O
]	O
Not	O
specified	O
€	O
793	O
.	O
60	O
(	O
31	O
–	O
6	O
,	O
394	O
)--(	O
all	O
ages	O
)	O
Aged	O
+	O
65	O
:	O
€	O
788	O
.	O
48	O
*	O
PHN	B-DS
defined	O
as	O
pain	O
persisting	O
for	O
one	O
month	O
following	O
resolution	O
of	O
HZ	B-DS
rash	O
.^	O
PHN	B-DS
defined	O
as	O
pain	O
persisting	O
for	O
three	O
months	O
following	O
resolution	O
of	O
HZ	B-DS
rash	O
.	O

The	O
total	O
annual	O
cost	O
(	O
direct	O
and	O
indirect	O
costs	O
)	O
of	O
HZ	B-DS
and	O
PHN	B-DS
on	O
a	O
country	O
level	O
basis	O
was	O
only	O
available	O
for	O
the	O
UK	O
[	O
43	O
],	O
France	O
[	O
30	O
],	O
Germany	O
[	O
31	O
],	O
Italy	O
[	O
29	O
]	O
and	O
Sweden	O
[	O
63	O
].	O

Two	O
studies	O
presented	O
data	O
separately	O
for	O
the	O
cost	O
of	O
HZ	B-DS
and	O
PHN	B-DS
and	O
patients	O
over	O
the	O
age	O
of	O
50	O
[	O
29	O
,	O
31	O
].	O

Further	O
details	O
are	O
provided	O
in	O
Figure	O
2	O
.	O
Figure	O
2	O
Estimated	O
total	O
cost	O
burden	O
associated	O
with	O
HZ	B-DS
and	O
PHN	B-DS
considering	O
outpatient	O
,	O
hospitalisation	O
and	O
indirect	O
costs	O
.	O

Humanistic	O
burden	O
and	O
impact	O
on	O
quality	O
of	O
life	O

A	O
total	O
of	O
21	O
EU	O
studies	O
[	O
7	O
,	O
14	O
,	O
15	O
,	O
21	O
,	O
25	O
,	O
28	O
,	O
42	O
,	O
44	O
,	O
48	O
,	O
50	O
,	O
56	O
-	O
58	O
,	O
62	O
,	O
65	O
,	O
66	O
,	O
68	O
,	O
75	O
-	O
77	O
]	O
reported	O
data	O
on	O
the	O
humanistic	O
burden	O
associated	O
with	O
HZ	B-DS
and	O
PHN	B-DS
,	O
with	O
the	O
significant	O
negative	O
impact	O
of	O
HZ	B-DS
and	O
PHN	B-DS
on	O
patients	O
’	O
HRQOL	O
consistently	O
reported	O
.	O

Of	O
note	O
,	O
pain	O
experienced	O
due	O
to	O
the	O
disease	O
was	O
found	O
to	O
interfere	O
with	O
many	O
aspects	O
of	O
patient	O
’	O
s	O
daily	O
life	O
.	O

Greater	O
interference	O
was	O
associated	O
with	O
increased	O
levels	O
of	O
pain	O
[	O
25	O
,	O
83	O
]	O
and	O
the	O
presence	O
of	O
PHN	B-DS
was	O
associated	O
with	O
a	O
greater	O
impact	O
on	O
most	O
domains	O
of	O
HRQoL	O
[	O
14	O
,	O
50	O
,	O
58	O
,	O
77	O
].	O

Patients	O
also	O
reported	O
consequences	O
for	O
their	O
family	O
and	O
social	O
circle	O
when	O
suffering	O
from	O
HZ	B-DS
or	O
PHN	B-DS
[	O
58	O
,	O
77	O
,	O
84	O
].	O

Pain	O
and	O
interference	O
with	O
daily	O
activities	O

Reports	O
within	O
the	O
reviewed	O
literature	O
indicate	O
that	O
patients	O
with	O
HZ	B-DS
and	O
PHN	B-DS
experience	O
moderate	O
-	O
severe	O
pain	O
.	O

Ratings	O
of	O
average	O
and	O
worst	O
pain	O
reported	O
in	O
the	O
literature	O
are	O
higher	O
among	O
PHN	B-DS
patients	O
compared	O
to	O
HZ	B-DS
patients	O
[	O
14	O
,	O
41	O
,	O
50	O
,	O
58	O
,	O
77	O
].	O

A	O
number	O
of	O
the	O
reviewed	O
articles	O
provided	O
data	O
from	O
the	O
Zoster	O
Brief	O
Pain	O
Inventory	O
(	O
ZBPI	O
)	O
and	O
the	O
Modified	O
Brief	O
Pain	O
Short	O
Form	O
(	O
mBPI	O
-	O
SF	O
)	O
c	O
–	O
derivative	O
measures	O
of	O
the	O
Brief	O
Pain	O
Inventory	O
(	O
BPI	O
)	O
which	O
require	O
patients	O
to	O
rate	O
the	O
level	O
of	O
interference	O
they	O
experience	O
on	O
a	O
scale	O
of	O
0	O
–	O
10	O
(‘	O
does	O
not	O
interfere	O
’	O
–	O
‘	O
completely	O
interferes	O
’),	O
across	O
seven	O
health	O
status	O
domain	O
;	O
general	O
activity	O
,	O
mood	O
,	O
walking	O
ability	O
,	O
normal	O
work	O
,	O
social	O
relations	O
,	O
sleep	O
and	O
enjoyment	O
of	O
life	O
.	O

Table	O
6	O
presents	O
the	O
mean	O
scores	O
for	O
patients	O
with	O
HZ	B-DS
and	O
PHN	B-DS
from	O
five	O
studies	O
.	O

In	O
general	O
,	O
reports	O
of	O
pain	O
interference	O
on	O
all	O
seven	O
health	O
status	O
domains	O
were	O
greater	O
among	O
patients	O
experiencing	O
PHN	B-DS
compared	O
to	O
patients	O
with	O
HZ	B-DS
[	O
14	O
,	O
50	O
,	O
58	O
,	O
77	O
].	O

HZ	B-DS
and	O
PHN	B-DS
patients	O
reported	O
sleep	O
to	O
be	O
the	O
aspect	O
of	O
their	O
daily	O
lives	O
most	O
affected	O
by	O
pain	O
(	O
4	O
.	O
5	O
-	O
4	O
.	O
9	O
and	O
6	O
.	O
3	O
-	O
6	O
.	O
5	O
mean	O
scores	O
respectively	O
),	O
while	O
walking	O
ability	O
was	O
the	O
least	O
affected	O
in	O
HZ	B-DS
patients	O
(	O
1	O
.	O
7	O
-	O
4	O
.	O
0	O
mean	O
score	O
)	O
and	O
enjoyment	O
of	O
life	O
was	O
least	O
affected	O
in	O
PHN	B-DS
patients	O
(	O
3	O
.	O
8	O
-	O
5	O
.	O
2	O
mean	O
score	O
)	O
[	O
14	O
,	O
15	O
,	O
50	O
,	O
58	O
,	O
77	O
].	O

Increased	O
levels	O
of	O
pain	O
are	O
reported	O
to	O
be	O
associated	O
with	O
increased	O
levels	O
of	O
interference	O
[	O
25	O
,	O
83	O
].	O

Levels	O
of	O
pain	O
interference	O
,	O
however	O
,	O
do	O
not	O
appear	O
to	O
be	O
associated	O
with	O
age	O
.	O

Lukas	O
et	O
al	O
.	O
[	O
58	O
]	O
presented	O
pain	O
interference	O
data	O
separately	O
for	O
six	O
European	O
countries	O
included	O
in	O
the	O
study	O
.	O

While	O
differences	O
in	O
the	O
level	O
of	O
interference	O
observed	O
varied	O
from	O
country	O
to	O
country	O
,	O
the	O
domains	O
of	O
health	O
status	O
most	O
affected	O
was	O
largely	O
consistent	O
.	O
Table	O
6	O
Level	O
of	O
pain	O
interference	O
across	O
seven	O
health	O
state	O
domains	O
as	O
assessed	O
by	O
the	O
ZBPI	O
(	O
or	O
similar	O
instrument	O
)	O
Health	O
state	O
domains	O
HZ	B-DS
(	O
mean	O
scores	O
)	O
PHN	B-DS
(	O
mean	O
scores	O
)	O
General	O
activity	O
3	O
.	O
8	O
-	O
4	O
.	O
43	O
.	O
1	O
-	O
5	O
.	O
7	O
Mood	O
3	O
.	O
4	O
-	O
4	O
.	O
53	O
.	O
4	O
-	O
5	O
.	O
9	O
Walking	O
ability	O
1	O
.	O
7	O
-	O
4	O
.	O
01	O
.	O
7	O
-	O
5	O
.	O
8	O
Normal	O
work	O
3	O
.	O
3	O
-	O
4	O
.	O
42	O
.	O
9	O
-	O
6	O
.	O
1	O
Social	O
relations	O
2	O
.	O
1	O
-	O
3	O
.	O
52	O
.	O
1	O
-	O
5	O
.	O
4	O
Sleep	O
4	O
.	O
5	O
-	O
4	O
.	O
96	O
.	O
3	O
-	O
6	O
.	O
5	O
Enjoyment	O
of	O
life	O
3	O
.	O
6	O
-	O
4	O
.	O
03	O
.	O
8	O
-	O
5	O
.	O
2Data	O
from	O
Bouhassira	O
2012	O
[	O
15	O
],	O
Gater	O
2014	O
[	O
50	O
],	O
Lukas	O
2012	O
[	O
58	O
],	O
Serpell	O
2014	O
[	O
14	O
],	O
Weinke	O
2010	O
[	O
77	O
].	O

Impact	O
on	O
general	O
health	O
-	O
related	O
quality	O
of	O
life	O

A	O
number	O
of	O
studies	O
have	O
included	O
generic	O
HRQoL	O
measures	O
such	O
as	O
the	O
SF	O
-	O
12	O
[	O
15	O
,	O
83	O
],	O
SF	O
-	O
36	O
[	O
14	O
,	O
21	O
,	O
50	O
],	O
EQ	O
-	O
5D	O
[	O
7	O
,	O
14	O
,	O
25	O
,	O
50	O
]	O
and	O
Short	O
Italian	O
Questionnaire	O
(	O
SIQ	O
)	O
[	O
75	O
,	O
76	O
]	O
to	O
assess	O
HRQoL	O
in	O
HZ	B-DS
and	O
PHN	B-DS
patients	O
.	O

Generally	O
,	O
HRQoL	O
has	O
found	O
to	O
be	O
inversely	O
associated	O
with	O
levels	O
of	O
reported	O
pain	O
[	O
14	O
,	O
25	O
,	O
50	O
,	O
83	O
]	O
and	O
the	O
poorest	O
HRQoL	O
has	O
been	O
observed	O
for	O
patients	O
with	O
PHN	B-DS
[	O
14	O
,	O
21	O
,	O
50	O
].	O

Consideration	O
of	O
HRQoL	O
scores	O
from	O
normative	O
populations	O
indicates	O
an	O
inverse	O
relationship	O
between	O
age	O
and	O
HRQoL	O
.	O

As	O
a	O
condition	O
mainly	O
inflicting	O
the	O
elderly	O
,	O
therefore	O
,	O
HRQoL	O
is	O
already	O
considerably	O
compromised	O
in	O
HZ	B-DS
and	O
PHN	B-DS
patients	O
.	O

Nonetheless	O
,	O
recent	O
research	O
indicates	O
that	O
both	O
HZ	B-DS
and	O
PHN	B-DS
patients	O
demonstrate	O
statistically	O
significant	O
and	O
clinically	O
relevant	O
deficits	O
in	O
HRQoL	O
when	O
scores	O
for	O
validated	O
measures	O
of	O
HRQoL	O
(	O
e	O
.	O
g	O
.	O
SF	O
-	O
36	O
and	O
EQ	O
-	O
5D	O
)	O
among	O
these	O
populations	O
are	O
compared	O
to	O
those	O
from	O
aged	O
-	O
matched	O
normative	O
samples	O
(	O
Figures	O
3	O
and	O
4	O
)	O
[	O
14	O
,	O
50	O
].	O
Figure	O
3	O
Comparison	O
of	O
SF	O
-	O
36	O
domain	O
and	O
component	O
scores	O
for	O
HZ	B-DS
patients	O
compared	O
to	O
age	O
-	O
matched	O
norms	O
[	O
50	O
].	O
No	O
*	O
s	O
p	O
≥	O
0	O
.	O
05	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
;	O
**	O
p	O
>	O
0	O
.	O
01	O
;	O
***	O
p	O
<	O
0	O
.	O
001	O
.	O
†	O
=	O
clinically	O
meaningful	O
PF	O
=	O
Physical	O
functioning	O
,	O
R	O
-	O
P	O
=	O
Role	O
-	O
physical	O
,	O
BP	O
=	O
Bodily	O
pain	O
,	O
GH	O
=	O
General	O
health	O
,	O
V	O
=	O
Vitality	O
,	O
SF	O
=	O
Social	O
functioning	O
,	O
R	O
-	O
E	O
=	O
Role	O
-	O
emotional	O
,	O
MH	O
=	O
Mental	O
health	O
,	O
PCS	O
=	O
Physical	O
component	O
summary	O
,	O
MCS	O
=	O
Mental	O
component	O
summary	O
.	O
Note	O
:	O
Data	O
collected	O
on	O
initial	O
presentation	O
of	O
HZ	B-DS
to	O
healthcare	O
professional	O
and	O
then	O
again	O
7	O
-	O
14	O
days	O
later	O
(	O
follow	O
-	O
up	O
).	O
Figure	O
4	O
Comparison	O
of	O
SF	O
-	O
36	O
domain	O
and	O
component	O
scores	O
for	O
PHN	B-DS
patients	O
compared	O
to	O
age	O
-	O
matched	O
norms	O
[	O
14	O
].	O
No	O
*	O
s	O
p	O
≥	O
0	O
.	O
05	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
;	O
**	O
p	O
<	O
0	O
.	O
01	O
;	O
***	O
p	O
<	O
0	O
.	O
001	O
.	O
†	O
=	O
clinically	O
meaningful	O
PF	O
=	O
Physical	O
functioning	O
,	O
R	O
-	O
P	O
=	O
Role	O
-	O
physical	O
,	O
BP	O
=	O
Bodily	O
pain	O
,	O
GH	O
=	O
General	O
health	O
,	O
V	O
=	O
Vitality	O
,	O
SF	O
=	O
Social	O
functioning	O
,	O
R	O
-	O
E	O
=	O
Role	O
-	O
emotional	O
,	O
MH	O
=	O
Mental	O
health	O
,	O
PCS	O
=	O
Physical	O
component	O
summary	O
,	O
MCS	O
=	O
Mental	O
component	O
summary	O
.	O

Impact	O
on	O
mood	O
and	O
mental	O
well	O
-	O
being	O

Data	O
presented	O
across	O
studies	O
demonstrates	O
that	O
patients	O
experience	O
a	O
negative	O
impact	O
on	O
their	O
mood	O
and	O
mental	O
well	O
-	O
being	O
,	O
with	O
patients	O
reporting	O
stress	O
,	O
anxiety	B-DS
and	O
depressive	O
symptoms	O
[	O
14	O
,	O
15	O
,	O
50	O
,	O
56	O
,	O
58	O
,	O
76	O
,	O
77	O
].	O

Across	O
studies	O
,	O
a	O
range	O
of	O
instruments	O
have	O
been	O
used	O
to	O
assess	O
the	O
impact	O
of	O
HZ	B-DS
and	O
PHN	B-DS
on	O
mood	O
,	O
including	O
the	O
Hospital	O
Anxiety	B-DS
and	O
Depression	B-DS
scale	O
(	O
HADS	O
)	O
[	O
7	O
,	O
15	O
],	O
10	O
,	O
47	O
Short	O
Italian	O
Questionnaire	O
(	O
SIQ	O
)	O
[	O
75	O
,	O
76	O
],	O
the	O
Short	O
Anxiety	B-DS
Screening	O
Test	O
(	O
SAST	O
)	O
[	O
56	O
]	O
and	O
bespoke	O
questions	O
[	O
58	O
,	O
77	O
].	O

Up	O
to	O
29	O
%	O
of	O
patients	O
with	O
HZ	B-DS
reported	O
feelings	O
of	O
moderate	O
anxiety	B-DS
or	O
depression	B-DS
,	O
rising	O
to	O
43	O
%	O
in	O
patients	O
with	O
PHN	B-DS
.	O

Further	O
,	O
a	O
larger	O
percentage	O
of	O
PHN	B-DS
patients	O
reported	O
extreme	O
anxiety	B-DS
or	O
depression	B-DS
(	O
11	O
%	O
vs	O
.	O
5	O
%)	O
[	O
58	O
,	O
77	O
],	O
evidencing	O
that	O
mood	O
and	O
mental	O
well	O
-	O
being	O
issues	O
are	O
greater	O
for	O
PHN	B-DS
patients	O
.	O

The	O
majority	O
of	O
patients	O
reported	O
experiencing	O
stress	O
some	O
of	O
the	O
time	O
(	O
up	O
to	O
78	O
%	O
for	O
HZ	B-DS
and	O
91	O
%	O
for	O
PHN	B-DS
)	O
or	O
most	O
of	O
the	O
time	O
(	O
up	O
to	O
19	O
%	O
HZ	B-DS
and	O
41	O
%	O
PHN	B-DS
)	O
[	O
58	O
,	O
77	O
].	O

Impact	O
on	O
family	O
and	O
social	O
relations	O

Up	O
to	O
50	O
%	O
of	O
patients	O
with	O
HZ	B-DS
and	O
81	O
%	O
of	O
patients	O
with	O
PHN	B-DS
reported	O
consequences	O
for	O
their	O
family	O
members	O
and	O
social	O
circle	O
[	O
58	O
,	O
77	O
].	O

Despite	O
the	O
high	O
proportion	O
of	O
patients	O
reporting	O
impacts	O
on	O
their	O
social	O
and	O
family	O
lives	O
,	O
only	O
three	O
studies	O
assessed	O
this	O
issue	O
beyond	O
comparing	O
scores	O
on	O
social	O
dimensions	O
of	O
instruments	O
such	O
as	O
the	O
ZBPI	O
or	O
SF	O
-	O
36	O
[	O
58	O
,	O
77	O
,	O
84	O
].	O

In	O
one	O
study	O
in	O
particular	O
,	O
one	O
fifth	O
of	O
the	O
respondents	O
felt	O
isolated	O
from	O
their	O
family	O
and	O
friends	O
while	O
suffering	O
from	O
HZ	B-DS
or	O
PHN	B-DS
,	O
with	O
19	O
%	O
and	O
27	O
%	O
of	O
patients	O
respectively	O
reporting	O
reduced	O
communication	O
during	O
their	O
illness	O
[	O
58	O
].	O

Of	O
note	O
,	O
impacts	O
were	O
not	O
limited	O
to	O
the	O
patient	O
themselves	O
,	O
with	O
findings	O
from	O
a	O
qualitative	O
focus	O
group	O
of	O
patient	O
’	O
s	O
relatives	O
demonstrating	O
that	O
relatives	O
were	O
worried	O
and	O
stressed	O
by	O
the	O
impact	O
of	O
HZ	B-DS
on	O
the	O
patients	O
[	O
84	O
].	O

Discussion	O

The	O
aim	O
of	O
this	O
article	O
was	O
to	O
provide	O
a	O
holistic	O
overview	O
of	O
the	O
published	O
literature	O
concerning	O
the	O
humanistic	O
,	O
economic	O
and	O
societal	O
burden	O
of	O
HZ	B-DS
and	O
PHN	B-DS
in	O
Europe	O
.	O

The	O
reviewed	O
evidence	O
highlights	O
the	O
significant	O
burden	O
of	O
HZ	B-DS
and	O
PHN	B-DS
for	O
patients	O
,	O
healthcare	O
systems	O
and	O
wider	O
society	O
.	O

A	O
number	O
of	O
key	O
findings	O
are	O
noted	O
.	O

Firstly	O
,	O
the	O
direct	O
costs	O
of	O
managing	O
HZ	B-DS
represent	O
a	O
significant	O
proportion	O
of	O
the	O
total	O
costs	O
associated	O
with	O
the	O
disease	O
,	O
with	O
higher	O
costs	O
associated	O
with	O
the	O
presence	O
of	O
PHN	B-DS
and	O
with	O
greater	O
pain	O
severity	O
.	O

Secondly	O
,	O
absenteeism	O
was	O
identified	O
as	O
a	O
significant	O
cost	O
driver	O
(	O
albeit	O
in	O
a	O
small	O
number	O
of	O
studies	O
),	O
with	O
up	O
to	O
65	O
%	O
of	O
employed	O
patients	O
reporting	O
work	O
absence	O
due	O
to	O
their	O
disease	O
.	O

Lastly	O
,	O
research	O
suggests	O
that	O
age	O
,	O
pain	O
severity	O
and	O
the	O
presence	O
of	O
PHN	B-DS
are	O
the	O
key	O
drivers	O
of	O
burden	O
to	O
patients	O
,	O
healthcare	O
systems	O
and	O
society	O
.	O

In	O
Europe	O
the	O
percentage	O
of	O
people	O
aged	O
65	O
years	O
or	O
over	O
is	O
projected	O
to	O
increase	O
from	O
17	O
.	O
1	O
%	O
(	O
84	O
.	O
6million	O
)	O
in	O
2008	O
to	O
30	O
.	O
0	O
%	O
(	O
151	O
.	O
5	O
million	O
)	O
in	O
2060	O
[	O
85	O
].	O

This	O
demographic	O
shift	O
is	O
likely	O
to	O
have	O
a	O
profound	O
influence	O
on	O
the	O
incidence	O
of	O
HZ	B-DS
and	O
PHN	B-DS
and	O
may	O
contribute	O
to	O
increased	O
concern	O
among	O
European	O
healthcare	O
authorities	O
;	O
particularly	O
if	O
economic	O
crisis	O
and	O
healthcare	O
budget	O
constrains	O
persist	O
in	O
the	O
long	O
term	O
.	O

Findings	O
from	O
this	O
review	O
indicate	O
that	O
the	O
direct	O
costs	O
of	O
HZ	B-DS
and	O
PHN	B-DS
management	O
are	O
greater	O
for	O
older	O
patients	O
.	O

In	O
addition	O
,	O
older	O
adults	O
typically	O
have	O
lower	O
HRQoL	O
than	O
younger	O
adults	O
(	O
deficits	O
which	O
are	O
more	O
pronounced	O
with	O
the	O
presence	O
of	O
HZ	B-DS
and	O
PHN	B-DS
)	O
and	O
may	O
be	O
less	O
able	O
to	O
complete	O
activities	O
of	O
daily	O
living	O
and	O
self	O
-	O
care	O
unassisted	O
.	O

The	O
potential	O
implications	O
of	O
an	O
aging	O
population	O
to	O
wider	O
society	O
,	O
therefore	O
,	O
are	O
wide	O
reaching	O
.	O

Limitations	O
of	O
the	O
current	O
literature	O
and	O
potential	O
gaps	O
that	O
provide	O
opportunities	O
for	O
future	O
research	O

A	O
number	O
of	O
limitations	O
concerning	O
the	O
currently	O
available	O
body	O
of	O
evidence	O
were	O
identified	O
.	O

Inconsistencies	O
in	O
data	O

There	O
is	O
currently	O
no	O
consensus	O
regarding	O
the	O
definition	O
of	O
PHN	B-DS
and	O
a	O
lack	O
of	O
consistency	O
in	O
the	O
definition	O
of	O
PHN	B-DS
employed	O
in	O
studies	O
was	O
evident	O
throughout	O
the	O
review	O
.	O

This	O
presents	O
a	O
number	O
of	O
challenges	O
when	O
attempting	O
to	O
accurately	O
understand	O
the	O
burden	O
of	O
HZ	B-DS
and	O
PHN	B-DS
.	O

For	O
example	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
the	O
prevalence	O
of	O
PHN	B-DS
varies	O
dramatically	O
depending	O
on	O
the	O
point	O
at	O
which	O
HZ	B-DS
-	O
related	O
pain	O
becomes	O
classified	O
as	O
PHN	B-DS
(	O
PHN1	O
or	O
PHN3	O
)	O
[	O
86	O
].	O

Accurately	O
attributing	O
costs	O
to	O
HZ	B-DS
and	O
PHN	B-DS
and	O
determining	O
the	O
overall	O
cost	O
burden	O
of	O
the	O
conditions	O
,	O
therefore	O
,	O
is	O
difficult	O
.	O

Similarly	O
,	O
cost	O
per	O
case	O
may	O
vary	O
dramatically	O
depending	O
on	O
the	O
definition	O
employed	O
.	O

For	O
this	O
reason	O
,	O
PHN	B-DS
definitions	O
employed	O
in	O
the	O
referenced	O
studies	O
have	O
been	O
highlighted	O
throughout	O
this	O
review	O
and	O
should	O
be	O
considered	O
when	O
interpreting	O
the	O
findings	O
from	O
individual	O
studies	O
.	O

Furthermore	O
,	O
there	O
is	O
a	O
lack	O
of	O
consistency	O
in	O
the	O
use	O
of	O
International	O
Classification	O
of	O
Diseases	O
(	O
ICD	O
)	O
codes	O
used	O
to	O
identify	O
PHN	B-DS
patients	O
in	O
clinical	O
practice	O
.	O

As	O
a	O
result	O
,	O
there	O
may	O
be	O
a	O
significant	O
proportion	O
of	O
PHN	B-DS
patients	O
who	O
have	O
not	O
been	O
considered	O
in	O
these	O
studies	O
;	O
consequently	O
decreasing	O
confidence	O
in	O
the	O
accuracy	O
of	O
estimates	O
regarding	O
the	O
burden	O
of	O
PHN	B-DS
.	O

A	O
lack	O
of	O
consistency	O
in	O
the	O
ways	O
in	O
which	O
data	O
had	O
been	O
collected	O
provides	O
further	O
difficulties	O
in	O
interpreting	O
and	O
comparing	O
the	O
available	O
data	O
across	O
studies	O
,	O
with	O
databases	O
,	O
patient	O
records	O
and	O
patient	O
surveys	O
all	O
utilized	O
.	O

For	O
example	O
,	O
rates	O
of	O
resource	O
use	O
were	O
derived	O
from	O
a	O
range	O
of	O
sources	O
including	O
:	O
analysis	O
of	O
patient	O
records	O
or	O
an	O
observed	O
sample	O
,	O
patient	O
responses	O
to	O
surveys	O
and	O
national	O
and	O
insurance	O
databases	O
,	O
with	O
each	O
of	O
these	O
methods	O
having	O
their	O
own	O
limitations	O
.	O

The	O
use	O
of	O
databases	O
is	O
a	O
valuable	O
way	O
of	O
gathering	O
data	O
at	O
a	O
national	O
level	O
,	O
however	O
it	O
assumes	O
information	O
is	O
recorded	O
consistently	O
and	O
accurately	O
across	O
databases	O
and	O
that	O
the	O
database	O
has	O
adequate	O
and	O
representative	O
population	O
coverage	O
.	O

Analysis	O
of	O
patient	O
records	O
assumes	O
information	O
is	O
accurately	O
recorded	O
by	O
GPs	O
,	O
who	O
have	O
a	O
myriad	O
of	O
demands	O
on	O
their	O
time	O
,	O
and	O
analysis	O
of	O
patient	O
’	O
s	O
responses	O
assumes	O
accuracy	O
in	O
their	O
recall	O
.	O

Of	O
note	O
,	O
the	O
incidence	O
of	O
hospitalisations	O
were	O
largely	O
based	O
on	O
rates	O
derived	O
from	O
databases	O
in	O
different	O
countries	O
,	O
or	O
rates	O
recorded	O
in	O
observed	O
samples	O
,	O
thus	O
inaccuracies	O
may	O
occur	O
when	O
these	O
data	O
are	O
extrapolated	O
to	O
the	O
country	O
population	O
.	O

Variation	O
in	O
reports	O
of	O
healthcare	O
resource	O
use	O
,	O
indirect	O
costs	O
and	O
humanistic	O
burden	O
are	O
also	O
likely	O
to	O
have	O
resulted	O
from	O
inconsistency	O
in	O
the	O
time	O
frame	O
that	O
different	O
studies	O
considered	O
relevant	O
.	O

With	O
respect	O
to	O
the	O
literature	O
on	O
economic	O
burden	O
,	O
it	O
is	O
understood	O
that	O
costs	O
are	O
likely	O
to	O
vary	O
between	O
countries	O
in	O
terms	O
of	O
the	O
cost	O
of	O
medical	O
resources	O
,	O
medical	O
visits	O
and	O
prescribed	O
medications	O
.	O

Currently	O
these	O
differences	O
are	O
not	O
reflected	O
in	O
the	O
published	O
literature	O
and	O
in	O
some	O
cases	O
,	O
the	O
cost	O
of	O
treating	O
a	O
case	O
of	O
HZ	B-DS
or	O
PHN	B-DS
were	O
calculated	O
inconsistently	O
,	O
with	O
some	O
studies	O
presenting	O
the	O
cost	O
per	O
treated	O
case	O
while	O
others	O
presented	O
the	O
average	O
across	O
all	O
patients	O
.	O

As	O
such	O
there	O
was	O
a	O
wide	O
variation	O
between	O
studies	O
.	O

Only	O
one	O
study	O
provided	O
costs	O
(	O
per	O
treated	O
case	O
)	O
for	O
the	O
different	O
types	O
of	O
medications	O
used	O
to	O
treat	O
HZ	B-DS
or	O
PHN	B-DS
[	O
46	O
].	O

Similarly	O
,	O
no	O
studies	O
provided	O
breakdown	O
or	O
clarification	O
of	O
cost	O
elements	O
included	O
in	O
a	O
‘	O
hospital	O
stay	O
’.	O

Great	O
caution	O
,	O
therefore	O
,	O
should	O
be	O
taken	O
in	O
comparing	O
and	O
interpreting	O
the	O
available	O
data	O
.	O

Furthermore	O
this	O
highlights	O
an	O
unmet	O
need	O
for	O
data	O
that	O
clearly	O
distinguishes	O
between	O
HZ	B-DS
and	O
PHN	B-DS
and	O
also	O
for	O
‘	O
per	O
treated	O
case	O
’	O
data	O
for	O
a	O
wide	O
range	O
of	O
EU	O
countries	O
.	O

A	O
further	O
notable	O
limitation	O
was	O
that	O
data	O
were	O
not	O
available	O
for	O
all	O
EU	O
countries	O
.	O

Despite	O
comprehensive	O
database	O
searches	O
,	O
in	O
which	O
no	O
restrictions	O
on	O
country	O
of	O
interest	O
or	O
language	O
of	O
publication	O
were	O
implemented	O
,	O
cost	O
burden	O
data	O
for	O
the	O
majority	O
of	O
Eastern	O
European	O
countries	O
was	O
not	O
identified	O
.	O

The	O
majority	O
of	O
studies	O
,	O
instead	O
,	O
focus	O
primarily	O
on	O
the	O
UK	O
,	O
Spain	O
,	O
France	O
,	O
Italy	O
,	O
Belgium	O
and	O
Germany	O
.	O

Gaps	O
in	O
evidence	O

A	O
number	O
of	O
evidence	O
gaps	O
were	O
identified	O
,	O
some	O
of	O
which	O
provide	O
opportunities	O
for	O
future	O
research	O
.	O

A	O
key	O
gap	O
identified	O
in	O
the	O
available	O
evidence	O
pool	O
relates	O
to	O
how	O
indirect	O
costs	O
are	O
assessed	O
.	O

While	O
a	O
number	O
of	O
EU	O
studies	O
presented	O
data	O
on	O
the	O
time	O
missed	O
from	O
work	O
and	O
associated	O
costs	O
,	O
data	O
on	O
productivity	O
while	O
at	O
work	O
and	O
associated	O
costs	O
is	O
lacking	O
.	O

Studies	O
in	O
the	O
US	O
and	O
Canada	O
,	O
however	O
,	O
report	O
that	O
presenteeism	O
could	O
account	O
for	O
up	O
to	O
75	O
%	O
of	O
the	O
cost	O
burden	O
associated	O
with	O
work	O
loss	O
[	O
87	O
]	O
and	O
that	O
an	O
average	O
of	O
46	O
hours	O
were	O
lost	O
(	O
per	O
employed	O
patient	O
)	O
due	O
to	O
presenteeism	O
[	O
88	O
].	O

In	O
Europe	O
,	O
decisions	O
regarding	O
access	O
and	O
reimbursement	O
of	O
medical	O
interventions	O
are	O
predominately	O
driven	O
by	O
considerations	O
of	O
cost	O
-	O
effectiveness	O
.	O

Consideration	O
of	O
the	O
impact	O
of	O
conditions	O
as	O
reported	O
by	O
patients	O
themselves	O
,	O
however	O
,	O
provides	O
important	O
information	O
regarding	O
unmet	O
need	O
and	O
the	O
efficacy	O
of	O
medical	O
interventions	O
.	O

A	O
number	O
of	O
studies	O
assessing	O
aspects	O
of	O
humanistic	O
burden	O
associated	O
with	O
HZ	B-DS
and	O
PHN	B-DS
were	O
identified	O
.	O

However	O
,	O
there	O
are	O
number	O
of	O
notable	O
limitations	O
.	O

Firstly	O
,	O
the	O
impact	O
of	O
HZ	B-DS
and	O
PHN	B-DS
was	O
generally	O
assessed	O
using	O
disease	O
specific	O
questionnaires	O
(	O
such	O
as	O
the	O
ZBPI	O
)	O
or	O
‘	O
bespoke	O
’	O
questions	O
which	O
have	O
not	O
been	O
tested	O
or	O
validated	O
.	O

There	O
was	O
only	O
limited	O
use	O
of	O
generic	O
HRQoL	O
instruments	O
in	O
the	O
EU	O
studies	O
conducted	O
to	O
date	O
.	O

However	O
,	O
data	O
from	O
such	O
instruments	O
are	O
valuable	O
for	O
quantifying	O
burden	O
with	O
reference	O
to	O
the	O
normative	O
population	O
and	O
patients	O
with	O
other	O
diseases	O
–	O
data	O
that	O
is	O
important	O
for	O
contextualizing	O
the	O
relative	O
burden	O
associated	O
with	O
HZ	B-DS
and	O
PHN	B-DS
.	O

The	O
available	O
evidence	O
does	O
not	O
typically	O
look	O
beyond	O
the	O
pain	O
which	O
accompanies	O
or	O
persists	O
beyond	O
the	O
rash	O
and	O
the	O
omission	O
of	O
other	O
factors	O
that	O
can	O
impact	O
on	O
patients	O
’	O
quality	O
of	O
life	O
(	O
e	O
.	O
g	O
.	O
fatigue	O
,	O
stomach	O
upsets	O
,	O
allodynia	O
,	O
and	O
numbness	O
).	O

This	O
should	O
be	O
addressed	O
,	O
preferably	O
through	O
a	O
combination	O
of	O
quantitative	O
and	O
qualitative	O
research	O
,	O
the	O
latter	O
of	O
which	O
was	O
notably	O
lacking	O
in	O
the	O
literature	O
.	O

Finally	O
,	O
the	O
lack	O
of	O
literature	O
relating	O
to	O
the	O
wider	O
societal	O
burden	O
potentially	O
caused	O
by	O
HZ	B-DS
and	O
PHN	B-DS
(	O
particularly	O
with	O
respect	O
to	O
the	O
impact	O
on	O
caregivers	O
and	O
the	O
broader	O
implications	O
of	O
HZ	B-DS
and	O
PHN	B-DS
on	O
provision	O
of	O
formal	O
and	O
informal	O
social	O
care	O
)	O
may	O
be	O
considered	O
a	O
critical	O
gap	O
.	O

To	O
date	O
burden	O
among	O
informal	O
caregivers	O
has	O
rarely	O
been	O
considered	O
,	O
and	O
only	O
in	O
terms	O
of	O
time	O
lost	O
from	O
work	O
.	O

Significantly	O
,	O
this	O
omits	O
the	O
potential	O
impacts	O
of	O
providing	O
informal	O
care	O
to	O
patients	O
that	O
may	O
not	O
have	O
resulted	O
in	O
time	O
lost	O
from	O
work	O
(	O
e	O
.	O
g	O
.	O
negative	O
impact	O
on	O
the	O
health	O
and	O
well	O
-	O
being	O
of	O
caregivers	O
).	O

Furthermore	O
,	O
consideration	O
of	O
healthcare	O
resource	O
use	O
and	O
the	O
economic	O
burden	O
of	O
HZ	B-DS
and	O
PHN	B-DS
has	O
typically	O
focussed	O
on	O
impacts	O
within	O
the	O
healthcare	O
system	O
;	O
the	O
broader	O
implications	O
of	O
HZ	B-DS
and	O
PHN	B-DS
are	O
rarely	O
appreciated	O
.	O

For	O
example	O
,	O
the	O
functional	O
deficits	O
observed	O
among	O
HZ	B-DS
and	O
PHN	B-DS
patients	O
that	O
may	O
lead	O
to	O
a	O
loss	O
of	O
autonomy	O
and	O
increased	O
reliance	O
on	O
formal	O
paid	O
care	O
have	O
not	O
been	O
estimated	O
.	O

Beyond	O
some	O
evidence	O
of	O
direct	O
and	O
indirect	O
costs	O
related	O
to	O
the	O
disease	O
,	O
the	O
potential	O
impact	O
of	O
HZ	B-DS
and	O
PHN	B-DS
on	O
the	O
social	O
care	O
system	O
remains	O
unknown	O
.	O

Conclusions	O

This	O
literature	O
review	O
highlights	O
the	O
burden	O
faced	O
by	O
patients	O
,	O
healthcare	O
systems	O
and	O
society	O
due	O
to	O
HZ	B-DS
and	O
PHN	B-DS
in	O
Europe	O
.	O

While	O
the	O
incidence	O
of	O
HZ	B-DS
and	O
PHN	B-DS
increases	O
with	O
age	O
,	O
the	O
total	O
cost	O
per	O
case	O
of	O
HZ	B-DS
and	O
PHN	B-DS
management	O
is	O
not	O
necessarily	O
age	O
-	O
dependent	O
.	O

Pain	O
severity	O
was	O
associated	O
with	O
increased	O
costs	O
for	O
both	O
HZ	B-DS
and	O
PHN	B-DS
,	O
and	O
,	O
as	O
a	O
chronic	O
condition	O
,	O
costs	O
were	O
higher	O
for	O
patients	O
experiencing	O
PHN	B-DS
.	O

No	O
study	O
fully	O
addressed	O
the	O
humanistic	O
and	O
economic	O
burden	O
of	O
HZ	B-DS
and	O
PHN	B-DS
to	O
patients	O
,	O
their	O
families	O
and	O
society	O
as	O
a	O
whole	O
.	O

Based	O
on	O
the	O
reviewed	O
evidence	O
and	O
an	O
assessment	O
of	O
the	O
gaps	O
in	O
the	O
evidence	O
base	O
,	O
it	O
is	O
likely	O
that	O
the	O
true	O
burden	O
of	O
HZ	B-DS
and	O
PHN	B-DS
is	O
underestimated	O
in	O
the	O
Europe	O
.	O

Further	O
research	O
is	O
required	O
to	O
build	O
a	O
holistic	O
understanding	O
of	O
the	O
impact	O
of	O
HZ	B-DS
and	O
PHN	B-DS
to	O
patients	O
,	O
healthcare	O
systems	O
and	O
society	O
.	O

Endnotes	O

a	O
*	O
Costs	O
originally	O
reported	O
in	O
2006	O
GBP	O
sterling	O
(£),	O
converted	O
to	O
euros	O
(€)	O
using	O
the	O
following	O
conversion	O
rate	O
£	O
1	O
=	O
€	O
1	O
.	O
18	O
.	O

b	O
*	O
Costs	O
originally	O
reported	O
in	O
2006	O
Swiss	O
francs	O
(	O
CHF	O
),	O
converted	O
to	O
euros	O
(€)	O
using	O
the	O
following	O
conversion	O
rate	O
1CHF	O
=	O
€	O
0	O
.	O
81	O
.	O

cAlthough	O
2	O
studies	O
do	O
not	O
report	O
a	O
specific	O
instrument	O
,	O
items	O
reported	O
appear	O
to	O
be	O
derived	O
from	O
the	O
ZBPI	O
(	O
38	O
,	O
55	O
).	O

Competing	O
interests	O

AG	O
and	O
RM	O
are	O
/	O
were	O
employees	O
of	O
Adelphi	O
Values	O
,	O
a	O
health	O
outcomes	O
agency	O
commissioned	O
by	O
Sanofi	O
Pasteur	O
MSD	O
,	O
to	O
conduct	O
,	O
analyse	O
and	O
communicate	O
findings	O
from	O
this	O
research	O
on	O
their	O
behalf	O
.	O

MU	O
and	O
EP	O
are	O
employees	O
of	O
Sanofi	O
Pasteur	O
MSD	O
,	O
a	O
provider	O
of	O
a	O
herpes	B-DS
zoster	I-DS
vaccine	O
approved	O
in	O
the	O
European	O
Union	O
.	O

The	O
authors	O
have	O
no	O
other	O
competing	O
interests	O
to	O
declare	O
.	O

Authors	O
’	O
contributions	O

AG	O
and	O
EP	O
designed	O
the	O
study	O
.	O

RA	O
and	O
AG	O
conducted	O
the	O
literature	O
searches	O
,	O
determined	O
eligibility	O
of	O
studies	O
for	O
inclusion	O
in	O
the	O
review	O
and	O
were	O
responsible	O
for	O
primary	O
data	O
extraction	O
and	O
analysis	O
.	O

EP	O
and	O
MU	O
contributed	O
to	O
the	O
analysis	O
.	O

AG	O
,	O
EP	O
and	O
MU	O
drafted	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

